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SUMMARY 
 
Allogeneic hematopoietic stem cell transplantation (HSCT) has been proposed 
to treat haematological malignancies since the 1960s. Unfortunately, pulmonary 
complications are frequent after this type of transplantation and are a major 
cause of post-transplant mortality.  
Induced sputum (IS) and measurement of exhaled nitric oxide (FeNO) are non-
invasive methods to investigate airway inflammation, which have been 
extensively used to assess airways inflammatory diseases. However, these 
procedures have not been studied in the context of HSCT.  
 
In the first part of this work, in an attempt to detect modifications at airway 
level, we monitored lung function and airway inflammation in 182 patients who 
underwent HSCT. We prospectively measured FEV1, FVC, DLCO, KCO, 
TLC, RV, FeNO as well as sputum cell counts before and 3, 6, 12, 24 and 36 
months after HSCT. We observed that there was a progressive loss in lung 
function after HSCT featuring a mild restrictive pattern while bronchiolitis 
obliterans rarely occurred (3.5%). Moreover, the patients undergoing a HSCT 
exhibited a high sputum neutrophil count, which was sustained over all the 
period of observation. By contrast, the FeNO value remained in the accepted 
normal range throughout the post-transplant course.  
The myeloablative (MA) conditioning was associated with early rise of sputum 
neutrophils and greater alteration in lung function over the first year. Overall 
survival at 1 year after HSCT were 71% and none of the baseline functional and 
airway inflammation features had a prognostic value for survival at one year.  
 
In a second part of our work, we measured Th1, Th2 and Th17 cytokines in the 
IS supernatant in order to better characterize the airway inflammatory process 
in patients with HSCT. Then, we compared the results with those from healthy 
subjects matched for age and tobacco habits and with patients suffering from 
chronic obstructive pulmonary disease (COPD), a chronic airway inflammatory 
disease also marked by a airway neutrophilic inflammation. We observed that 
that patients undergoing HSCT display raised sputum levels of IL-6 and IL-8 
compared to healthy subjects though the levels remained lower than those 
found in COPD. 
 
In the third part of our work, we assessed the impact of mesenchymal stem cell 
(MSC) co-infusion on lung function after HSCT. Indeed, MSC are used to 
promote engraftment and prevent graft-versus-host-disease in the context of 
HSCT but were shown to have opposite effects on lungs after systemic 
administration in animals. Their effects have never been studied in human after 
HSCT. Thus, we monitored lung functions, FeNO values, the occurrence of 
pulmonary infections and cytomegalovirus (CMV) reactivation in 30 patients 
who received an allogeneic unrelated HSCT after non-myeloabaltive (NMA) 
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conditioning with MSC co-infusion. They were compared with 28 patients 
undergoing the same type of transplantation and conditioning but without MSC 
infusion. The impact of MSC on pulmonary infections and CMV reactivation 
was analysed by uni and multivariate Cox models adjusted for competing risks. 
The principal observations were that MSC were safe at lung level after HSCT 
and did not lead to lung function changes 1 year post transplantation. However, 
MSC could promote pulmonary infections involving the need for a close 
monitoring of their occurrence. 
 
Conclusion 
 
There was a progressive loss in lung function after HSCT, featuring a 
restrictive pattern. Myeloablative conditioning was associated with early rise of 
sputum neutrophils and greater alteration in lung function over the first year. 
Moreover, patients undergoing HSCT exhibited a neutrophilic airway 
inflammation associated with raised sputum levels of IL-6 and IL-8, a picture 
similar but developed to a lesser extent of what is seen in COPD. 
Finally, MSC co-infusion did not induce pulmonary deterioration 1 year after 
HSCT with NMA conditioning. MSC appeared to be safe for the lung but close 
monitoring of pulmonary infections remains essential. 
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RESUME 
 
La greffe allogénique de cellules souches hématopoiétiques est utilisée pour 
traiter les hémopathies malignes depuis les années 60. Malheureusement, les 
complications pulmonaires sont fréquentes après ce type de greffe et 
représentent une cause majeure de mortalité. 
L’expectoration induite et la mesure de l’oxyde nitrique exhalé (FeNO) sont 
des méthodes non-invasives permettant d’investiguer l’inflammation des voies 
aériennes qui ont été largement utilisées pour évaluer les maladies 
inflammatoires des voies respiratoires. Cependant, ces procédures n’ont jamais 
été étudiées dans le contexte de la greffe de cellules souches hématopoiétiques.  
 
Dans la première partie de ce travail, dans le but de détecter les modifications 
au niveau des voies aériennes, nous avons suivi la fonction pulmonaire et 
l’inflammation des voies aériennes chez 182 patients ayant subi une greffe. 
Nous avons mesuré de manière prospective le VEMS, la CVF, la DLCO, le 
KCO, la CPT, le VR et le FeNO ainsi que la cytologie de l’expectoration 
induite avant et 3, 6, 12, 24 et 36 mois après la greffe. Nous avons observé une 
chute progressive de la fonction pulmonaire après greffe figurant un léger 
syndrôme restrictif tandis que l’apparition d’une bronchiolite oblitérante était 
rare (3.5% des patients). De plus, les patients ayant subi une greffe de cellules 
souches hématopoiétiques présentaient un taux élevé de neutrophiles dans les 
expectorations qui persistait pendant toute la période d’observation. A l’opposé, 
la valeur du FeNO est restée dans les valeurs normales pendant tout le suivi. Le 
conditionnement myéloablatif (MA) était associé à une élévation précoce du 
taux de neutrophiles dans les expectorations et une altération plus importante de 
la fonction pulmonaire pendant la première année après greffe. La survie 
globale à 1 an était de 71% et aucune caractéristique fonctionnelle ou 
inflammatoire avant greffe n’est apparue avoir une valeur pronostique de la 
survie à 1 an. 
 
Dans la seconde partie de ce travail, nous avons mesuré des cytokines Th1, Th2 
et Th17 dans le surnageant d’expectoration dans le but de mieux caractériser 
l’inflammation des voies respiratoires chez les patients greffés. Nous avons 
ensuite comparé les résultats avec ceux provenant de volontaires sains matchés 
pour l’âge et le statut tabagique et également avec des patients atteints de 
bronchopneumonie obstructive chronique (BPCO), une maladie chronique des 
voies respiratoires également caractérisée par une inflammation neutrophilique. 
Nous avons observé que les patients subissant une greffe de cellules souches 
hématopoiétiques présentaient une augmentation du taux d’IL-6 et d’IL-8 dans 
le surnageant d’expectoration comparés à des sujets sains bien que ces taux 
demeuraient plus faibles que ceux observés chez des patients BPCO. 
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Dans la troisième partie de ce travail, nous avons évalué l’impact de la co-
infusion de cellules souches mésenchymateuses (MSC) sur la fonction 
pulmonaire après greffe. En effet, les MSC sont utilisées pour promouvoir la 
prise de greffe et prévenir la réaction du greffon contre l’hôte lors de greffe de 
cellules souches hématopoiétiques mais il a été démontré qu’elles pouvaient 
avoir des effets contradictoires sur le poumon après administration par voie 
générale chez l’animal. Leur effet n’a jamais été étudié à ce niveau après greffe 
chez l’humain. Ainsi, nous avons surveillé la fonction pulmonaire, la valeur du 
FeNO, l’apparition d’infections pulmonaires et la réactivation du 
cytomégalovirus (CMV) chez 30 patients ayant reçu une greffe allogénique 
non-familiale après un conditionnement non-myeloablatif (NMA) et une co-
infusion de MSC. Ces patients ont été comparés avec 28 patients ayant reçu le 
même type de transplantation et de conditionnement mais sans co-infusion de 
MSC. L’impact des MSC sur l’apparition d’infections pulmonaires et sur la 
réactivation du CMV a été analysé par un modèle de Cox uni et multivarié 
ajusté pour les risques compétitifs. Les principales observations ont été que la 
co-infusion de MSC était sans danger au niveau pulmonaire et n’a pas entrainé 
de changement de fonction respiratoire 1 an après la greffe. Cependant, la co-
infusion de MSC pourrait promouvoir les infections pulmonaires, nécessitant 
un suivi étroit de leur apparition. 
 
Conclusion 
 
Nous avons observé une chute progressive de la fonction respiratoire après 
greffe de cellules souches hématopoiétiques figurant un syndrôme restrictif. Le 
conditionnement myéloablatif était lié à une augmentation précoce du taux de 
neutrophiles dans les expectorations et une plus grande altération de la fonction 
pulmonaire dans la première année après greffe. De plus, les patients subissant 
une greffe de cellules souches hématopoiétiques présentaient une inflammation 
neutrophilique des voies respiratoires associée à une augmentation des taux 
d’IL-6 et d’IL-8 dans les expectorations, une image similaire mais moins 
prononcée que celle observée lors de BPCO. Finalement, la co-infusion de 
MSC n’a pas induit de détérioration au niveau pulmonaire 1 an après greffe 
associée à un conditionnement non-myeloablatif. La co-infusion de MSC 
apparait sans danger au niveau pulmonaire, cependant, un suivi étroit des 
infections pulmonaires demeure essentiel. 
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SAMENVATTING 
 
Allogene hematopoïetische stamceltransplantatie (HSCT) wordt gebruikt voor 
de behandeling van hematologische maligniteiten sinds de jaren zestig. Helaas 
komen na dit type transplantaties vaak pulmonale complicaties voor die de 
grootste oorzaak van post-transplantatie mortaliteit zijn. Geïnduceerd sputum 
(IS) en metingen van uitgeademde Stikstof Monoxide (FeNO) zijn niet-
invasieve methoden voor het onderzoeken van luchtweginflammatie die 
uitgebreid gebruikt worden om inflammatoire longziektes te evalueren. Deze 
methodes zijn echter nog niet onderzocht in het kader van  HSCT. 
 
In het eerste deel van dit werk, in een poging om veranderingen ter hoogte van 
de luchtwegen op te sporen, werden bij 182 patiënten die een transplantatie 
ondergingen de longfunctie en de luchtweginflammatie gecontroleerd. 
Prospectief werden de longfunctiewaarden FEV1, FVC, DLCO, KCO, TLC, 
RV, FeNO alsook de hoeveelheid cellen in het sputum gecontroleerd vóór de 
transplantatie en 3, 6, 12, 24 en 36 maanden erna.  
Na de transplantatie werd een progressieve daling van de longfunctie 
vastgesteld in combinatie met een mild restrictief syndroom terwijl 
bronchiolitis obliterans zelden voorkwam (3.5%). Bovendien vertoonden de 
patiënten die een HSCT ondergingen een hoog aantal neutrofielen in hun 
sputum en dit gedurende de hele observatieperiode. De FeNO waarden 
daarentegen bleven binnen de normaalwaarden gedurende de gehele periode. 
De myeloablatieve (MA) conditionering ging gepaard met een vroege stijging 
van het aantal neutrofielen in het sputum en een grotere verandering van de 
longfunctie tijdens het eerste jaar na de transplantatie. De globale overleving 1 
jaar na transplantatie was 71% en geen van de functionele of inflammatoire 
kenmerken vóór de transplantatie bleken een prognostische waarde te hebben 
voor de overlevingskansen na 1 jaar.  
 
In het tweede deel van het onderzoek werden Th1, Th2 en Th17 cytokines 
bepaald in het supernatans van het geïnduceerd sputum om een beter inzicht te 
krijgen in het ontstekingsproces van de luchtwegen bij patiënten met HSCT. 
Vervolgens werden de resultaten vergeleken met deze van gezonde 
vrijwilligers, gematcht voor leeftijd en rookgewoontes, alsook met deze van 
patiënten die leden aan COPD (chronisch obstructief longlijden), een 
chronische inflammatoire longziekte ook gekenmerkt door een neutrofiele 
inflammatie. Bij patiënten die een HSCT ondergingen, werd een verhoging van 
de IL-6 en IL-8 waarden in het sputum vastgesteld in vergelijking met gezonde 
personen. Toch bleven de waarden onder deze vastgesteld bij patiënten met 
COPD. 
In het derde deel van ons onderzoek werd de impact van co-infusie met 
mesenchymale stamcellen (MSC) op de longfunctie na transplantatie 
geëvalueerd. MSC worden immers gebruikt om het aanslaan te bevorderen en 
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om graft-versus-host ziekte te voorkomen bij HSCT. Er werd echter 
aangetoond dat deze een tegenovergesteld effect kunnen hebben op de longen 
na systemische toediening bij dieren. Hun effect werd nooit bestudeerd in 
mensen na HSCT. Dus werden de longfuncties, de FeNO waarde, de 
aanwezigheid van pulmonaire infecties en CMV (cytomegalovirus) reactivatie 
gecontroleerd in 30 patiënten die een allogene niet-gerelateerde HSCT 
ondergingen na een non-myeloablatieve (NMA) conditionering met een co-
infusie van MSC. Zij werden vergeleken met 28 patiënten die eenzelfde type 
transplantatie en conditionering ondergingen, maar zonder co-infusie van MSC. 
De impact van MSC op pulmonaire infecties en CMV reactivatie werd 
geanalyseerd met een uni- en multivariant Cox model aangepast aan 
concurrerende risico’s. De voornaamste observaties waren dat de co-infusie van 
MSC veilig was na HSCT met betrekking tot de longen en geen veranderingen 
van de longfunctie 1 jaar na transplantatie veroorzaakte. De co-infusie van 
MSC zou echter wel pulmonaire infecties kunnen bevorderen, met de noodzaak 
deze nauwlettend op te volgen. 
 
Conclusie 
 
Na HSCT werd een progressieve daling van de longfunctie vastgesteld in 
combinatie met een mild restrictief syndroom. De myeloablatieve (MA) 
conditionering ging gepaard met een vroege stijging van het aantal neutrofielen 
in het sputum en een grotere verandering van de longfunctie tijdens het eerste 
jaar na transplantatie. Bovendien vertoonden de patiënten die een HSCT 
ondergingen een neutrofiele luchtweginflammatie in associatie met verhoogde 
IL-6 en IL-8 waarden in het sputum, een beeld vergelijkbaar met dat bij COPD 
patiënten, maar minder uitgesproken. 
Co-infusie van MSC gaf geen aanleiding tot een verslechtering van de 
longfunctie 1 jaar na HSCT met NMA conditionering. MSC zou blijkbaar 
veilig zijn voor de longen, maar een nauwlettende opvolging van pulmonaire 
infecties blijft essentieel. 
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INTRODUCTION 
 
1. Hematopoietic stem cell transplantation 
 
1.1. Definition 
 
Allogeneic hematopoietic stem cell transplantation (HSCT) is defined as the 
transplantation of pluripotent hematopoietic stem cells from a healthy donor to 
a recipient. These cells are able to regenerate all hematopoietic tissues leading 
to replacement of the bone marrow of the recipient by the donor cells. HSCT is 
performed in patients who are suffering from hematological malignancies and 
other immuno-hematopoietic disorders. An association of a conditioning and an 
immunological conflict, linked to the donor T lymphocytes, mediates the 
eradication of malignant cells1-3. The graft is composed of stem cells, but 
contains also immune cells such as T cells, NK and monocytes. Stem cells are 
responsible for the hematological and long-term immune reconstitution (> 6 
months) and T cells are linked to early immune recovery. Historically, the use 
of HSCT began in the 50‘s when it was shown that the transplantation of bone 
marrow cells to irradiated rodents could prevent death from marrow failure4-8. 
The first attempt in humans was performed by Thomas et al9 in 1957 and his 
team received the Nobel Prize in Medicine in 1990 for his further work and 
discoveries on bone marrow transplantation10. After many years of 
improvements, concerning Human Leucocyte Antigen (HLA) compatibility and 
immunosuppressive management, HSCT is currently a routine procedure for 
patients with a variety of hematological disorders and nowadays, more than 50 
000 transplantations are performed yearly worldwide (www.bmdw.org). 
 
1.2. Indications 
 
Allogeneic HSCT has been used to treat hematological diseases, solid tumors 
and selected nonmalignant disorders. Hematological malignancies can be 
classified as acute or chronic and as deriving from the lymphoid or myeloid 
lineages. They can develop in the bone marrow (leukemia) or in lymph nodes 
(lymphoma). They include therefore chronic or acute myeloid leukemia, 
chronic or acute lymphoid leukemia, myelodysplastic or myeloproliferative 
syndromes, non-Hodgkin’s lymphoma, Hodgkin’s lymphoma and multiple 
myeloma (Table 1). Allogeneic transplantation for hematologic cancers offers 
the best chance for cure in case of first remission in patients with a poor 
prognosis with conventional chemotherapy. It is also used after relapse in 
patients with a favorable prognosis with chemotherapy.  
The eligibility for HSCT depends on the type and stage of the underlying 
malignancy, patient age and health status. 
 
  20 
Table 1: indications of allogeneic transplant procedures for adults, current 
practice in Europe 2009 
 
Disease Disease status Sibling donor Well matched 
unrelated 
donor 
mm unrelated  
> 1 Ag mm 
related 
Leukemia     
AML CR1 (low risk) 
CR1 (intermediate) 
CR1 (high reisk) 
CR2 
CR3, incipient relapse 
M3 molecular persistence M3 
molecular CR2 
Relapse or refractory 
CO 
S 
S 
S 
S 
S 
S 
CO 
 
D 
CO 
S 
S 
CO 
CO 
CO 
D 
GNR 
D 
CO 
CO 
D 
GNR 
GNR 
D 
ALL CR1 (standart/intermediate) 
CR1 (high risk) 
CR2, incipient relapse 
Relapse or refractory 
 
D 
S 
S 
CO 
 
GNR 
S 
S 
D 
 
GNR 
CO 
CO 
D 
CML First chronic phase (CP), faling 
imatinib 
Accelerated phase or > first CP 
Blast crisis 
S 
 
S 
CO 
S 
 
S 
CO 
CO 
 
CO 
CO 
 
Myelofibrosis 
 
Primary or secondary with an 
intermediate or high Lille score 
 
 
S 
 
S 
 
D 
Myelodysplastic  
syndrome 
RA, RAEB 
RAEBt, sAML in CR1 or CR2 
More advanced stages 
S 
S 
S 
S 
S 
CO 
CO 
CO 
D 
 
CLL 
 
Poor-risk disease 
 
S 
 
S 
 
D 
     
Lymphomas 
Diffuse large B-cell 
lymphoma 
 
Mantle cell 
lymphoma 
 
Lymphoblastic 
lymphoma and 
Burkitt’s 
lymphoma 
 
Follicular B-cell 
NHL 
 
T-cell NHL 
 
 
Hodgkin’s 
lymphoma 
 
Lymphocyte 
predominant 
 
CR1 (intermediate/high IPI at dx) 
Chemosensitive relapse; ≥ CR2 
Refractory 
 
CR1 
Chemosensitive relapse; ≥ CR2 
Refractory 
 
CR1 
Chemosensitive relapse; ≥ CR2 
Refractory 
 
 
CR1 (intermediate/high IPI at dx) 
Chemosensitive relapse; ≥ CR2 
Refractory 
 
CR1 
Chemosensitive relapse; ≥ CR2 
Refractory 
 
CR1 
Chemosensitive relapse; ≥ CR2 
Refractory 
 
CR1 
Chemosensitive relapse; ≥ CR2 
Refractory 
 
GNR 
CO 
D 
 
CO 
CO 
D 
 
CO 
CO 
D 
 
 
GNR 
CO 
CO 
 
CO 
CO 
D 
 
GNR 
CO 
D 
 
GNR 
GNR 
GNR 
 
GNR 
CO 
D 
 
D 
D 
D 
 
CO 
CO 
D 
 
 
GNR 
CO 
CO 
 
D 
CO 
D 
 
GNR 
CO 
D 
 
GNR 
GNR 
GNR 
 
GNR 
GNR 
GNR 
 
GNR 
GNR 
GNR 
 
GNR 
GNR 
GNR 
 
 
GNR 
D 
D 
 
GNR 
GNR 
GNR 
 
GNR 
CO 
GNR 
 
GNR 
GNR 
GNR 
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nodular HL 
 
Other diseases 
Myeloma 
Amyloidosis 
Severe aplastic 
anemia 
 
PNH 
Breast cancer 
Breast cancer 
Germ cell tumours 
 
 
 
 
 
Newly diagnosed 
Relapsed/refractory 
 
 
 
CO 
CO 
S 
S 
 
 
 
S 
GNR 
D 
GNR 
 
 
 
CO 
CO 
CO 
S 
 
 
 
CO 
GNR 
D 
GNR 
 
 
 
GNR 
GNR 
CO 
CO 
 
 
 
CO 
GNR 
GNR 
GNR 
Germ cell tumours 
Ovarian cancer 
Ovarian cancer 
Medulloblastoma 
Small-cell lung 
cancer 
Renal cell 
carcinoma 
Soft cell sarcoma 
including 
Immune cytopenias 
Systemic sclerosis 
Rheumatoid 
arthritis 
Multiple sclerosis 
SLE 
Crohn’s disease 
CIDP 
 
 
 
Third-line refractory 
CR/PR 
Platinum-sensitive relapse 
Post-srugery 
Limited 
 
 
Metastatic, cytokine-refractory 
 
Metastatic, responding 
 
GNR 
GNR 
D 
GNR 
GNR 
 
 
CO 
 
D 
 
 
CO 
 
D 
GNR 
 
D 
 
D 
GNR 
GNR 
 
GNR 
GNR 
GNR 
GNR 
GNR 
 
 
CO 
 
GNR 
 
 
D 
 
GNR 
GNR 
 
GNR 
 
GNR 
GNR 
GNR 
 
GNR 
GNR 
GNR 
GNR 
GNR 
 
 
GNR 
 
GNR 
 
 
D 
 
GNR 
GNR 
 
GNR 
 
GNR 
GNR 
GNR 
Adapted from Ljungman, Bone Marrow Transplantation 201011 
CIDP= chronic inflammatory demyelinating polyradiculoneuropathy; CO= clinical option; can be carried 
after assessment of risks and benefits; CR1, 2, 3= first, second, third complete remission; D= 
developmental; further trials are needed; GNR= generally not recommended; IPI= international prognostic 
index; mm= mismatched; MRD= minimal residual disease; PNH= paroxysmal nocturnal hemoplobinuria; 
RA= refractory anaemia; RAEB= refractory anaemia with excess blasts, S= standart of care; generally 
indicated in suitable patients; sAML= secondary acute myeloid leukaemia; SLE= systemic lupus 
erythematosus. Low-intermediate-high categories are based mainly on number of white blood cells, 
cytogenetics at diagnosis and molecular markers, and time to achieve remission according to international 
trials. 
This classification does not cover patients for whom a syngeneic donor is available 
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1.3. Conditioning 
 
To allow the donor cell engraftment, the immune system of the recipient is 
previously destroyed by a conditioning based on irradiation and/or 
chemotherapy. Another important role of this conditioning is the eradication of 
tumor cells.  Since the 90s, an association of total body irradiation (TBI) and 
cyclophosphamide has been the standard regimen12,13. 
However, because of high toxicity of the conditioning, patients over 55 years 
were considered as non-eligible 14. The fact that these hematological diseases 
develop mainly between 60 and 70 years leaded to the development of reduced 
intensity conditioning in the 90’s15-17. Non-myeloablative conditioning uses 
lower doses of radiation and/ or chemotherapeutic agents and can be performed 
in case of elderly patients or patients with comorbidities, i.e. considered 
ineligible for high dose conventional conditioning18. 
After non-myeloablative conditioning, eradication of cancer cells is performed 
by the Graft versus Tumor reaction instead of high dose cytotoxic agents, and 
this effect is mediated by the donor T cells. It initially allows the establishment 
of a mixed hemopoietic chimerism defined as the co-existence of donor and 
recipient hematopoietic cells that should evolve into full donor chimerism. 
This type of regimen induces less organ damages (on gastro-intestinal tract, 
kidneys, liver, lungs)19,20 than myeloablative conditioning. In addition, the 
neutropenia phase is shorter21 leading to less bacterial infections early after 
HSCT22. The need for red blood cell transfusions is also decreased23 and the 
patient follow-up can be done in an ambulatory care setting.  
The incidence of grade II-IV acute Graft-Versus-Host-Disease (aGVHD)24 is 
lower after this kind of conditioning compared to myeloablative conditioning 
but the rate of chronic GVHD (cGVHD) remains similar. The mortality is 
mainly due to relapse or GVHD. A common example of non-myeloablative 
conditioning combines a purine analog (Fludarabine) and total body irradiation 
(TBI, 2 grays (Gy))25. This combination was set up by Storb et al and is use in 
association with post-transplant immunosuppression consisting in ciclosporine 
and mycophenolate mofetil to prevent GVHD. 
 
1.4. Type of transplant 
 
Hematopoietic stem cells may be derived from the bone marrow, the peripheral 
blood or the umbilical cord blood. To collect peripheral blood stem cells or 
PBSCs, the donor is injected for 5-6 days with granulocyte colony-stimulating 
factor (G-CSF) that induces the mobilization of high stem cell numbers from 
the bone marrow to the peripheral blood. These cells are then harvested by 
apheresis. Compared to bone marrow, PBSCs contain an increased number of 
nucleated cells, natural killer (NK) and CD34-positive (surface marker of 
hematopoietic cells) and CD3-positive (T-cell marker) cells. Although PBSCs 
compared to bone marrow allow faster engraftment, the cGHVD incidence 
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appears higher. The aGVHD incidence seemed to be similar and the overall 
survival similar or even increased26-28.  
As all patients do not have an available sibling or unrelated donor, especially 
for patients from racial or ethnic minorities, alternative stem cell sources were 
needed. 
Since the 80s, the umbilical cord blood (UCB) is also used as a source of 
transplantable cells29. It contains sufficient numbers of hematopoietic stem cells 
and low numbers of mature T cells, allowing some degree of HLA mismatch. 
Advantages also include a rapid availability and a reduced risk of GHVD30. 
Nevertheless, the graft failure rate is increased and the immune reconstitution is 
delayed, leading to a higher infection rate31. Furthermore, cord blood units 
contain a limited number of hematopoietic stem cells, so their use in adult 
patients is limited due to the recommended cell dose but results continue to 
improve. Today, more than 500 000 cord blood units are available in cord 
blood banks around the world (www.bmdw.org). 
 
1.5. Type of donor  
 
The transplanted stem cells may come from the recipient himself in case of 
autologous transplantation or are allogeneic when the cells come from another 
person than the recipient himself. The donor can be related or unrelated to the 
recipient. The HLA mismatch level between the donor and the recipient is 
linked to the occurrence of graft rejection as well as GVHD. The importance of 
a complete (10/10) matching for HLA A, B, C, DRB1 and DQB1 has been 
established32. The ideal situation is the identification of a sibling with the same 
HLA haplotypes. A twin donor, although being the most suitable donor in 
immunological terms, is associated with higher relapse risk because of the lack 
of GVT effects33. Partially HLA-identical family members can also be used 
with reasonable success rates.  
Only around 30% of recipients have a suitable family donor, therefore the use 
of HLA-matched unrelated donors has increased during the last decades and 
results appear similar to what is observed with identical sibling donors when a 
10/10 matched donor is used34,35. Nowadays, large registries of volunteer 
donors are established and around 20 million donors are available worldwide. 
Nevertheless, this type of transplantation is associated with delayed immune 
reconstitution leading to higher infection incidence36. 
 
 
1.6. Graft-Versus-Tumor effect  
 
The graft-versus-tumor (GVT) effect was discovered in the 70-80s37,38 although 
already suggested by Barnes et al. in the 50s39. It is linked to donor cells present 
in the graft such as CD4 and CD8 T cells, macrophages, dendritic cells and NK 
cells. These cells are responsible for the destruction of malignant cells and 
  24 
decrease the relapse risk, although T cells also increase the risk of GVHD. The 
GVT reaction depends mainly on the T cells as T-cells depletion of the graft 
reduces it strongly40,41. 
It seems that T cells are directed against minor histocompatibility antigens 
(mHLA) recognized on the normal (leading to GVHD) and tumor recipient 
cells42-44. In this context, donor lymphocyte infusions (DLI) have been used to 
treat patients relapsing after tranplantation, especially in those with chronic 
myeloid leukemia45,46. However, the major complications of DLI include 
GVHD and marrow aplasia.  
 
 
1.7. Graft-Versus-Host Disease  
 
Graft-versus-Host disease (GVHD) remains an important limitation of the 
allogeneic HSCT, which disrupts the quality of life of the patient. This reaction 
is due to the donor cells recognizing the recipient cells as foreign and mounting 
an immunological attack47. The underlying mechanism is based on the 
recognition of the recipient major (HLA system) or minor histocompatibility 
molecules by T cells of the donor48.  
GVHD can be classified as acute or chronic depending on the time when it 
appears after the HSCT. 
 
- Acute GVHD (aGVHD) occurs within 100 days after HSCT, often within 2 to 
6 weeks. The major risk factors include HLA-mismatches, unrelated donor, 
CMV infection and high dose conditioning49. It occurs in up to 50% of HLA-
matched and 70% of HLA-mismatched recipients50. AGVHD may involve the 
skin, liver, digestive tractus and lead to rash, jaundice, diarrhea or intestinal 
bleeding respectively51. This is due to apoptosis of epithelial cells of these 
organs. AGVH is responsible for 10 to 30 % of deaths observed after HSCT. 
AGVHD is classified according to the injury severity from grade 0 (mild) to IV 
(very severe)52. The physiopathology involves, first, host tissue injuries linked 
to pre-transplant conditioning. The epithelial and endothelial injuries induce the 
production of pro-inflammatory chemokines and cytokines such as interleukin 
(IL)-1 and tumor necrosis factor (TNF)-alpha. At gastrointestinal level, 
damages due to conditioning induce a translocation of bacterial 
lipopolysaccharides (LPS). The release of these cytokines and LPS is 
responsible for an over-expression of adhesion and major and minor 
histocompatibility molecules on recipient cells. The recognition of these 
molecules is then facilitated. The second phase corresponds to the 
implementation of an immune response and depends on the interactions 
between antigen-presenting cells (APCs) and donor T lymphocytes. This 
phenomenon leads to the production of Th1 pro-inflammatory cytokines such 
as IL-2, IL-15 and IFN-gamma. The latter activates NK cells and macrophages. 
Inflammatory mediators are released such as TNF-alpha, IFN-gamma, nitric 
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oxide (N0) as well as IL-1, which amplify the tissue injury. Others cytokines 
were also shown to play a role in the development of aGVHD including Th2 
cytokines (IL-4, IL-5, IL-6, and IL-10)53. The last phase is based on apoptosis 
of target cells by T lymphocytes and NK cells. AGVD progression can thus be 
summarized in three phases: 1) activation of APCs, 2) donor T cell activation, 
proliferation, differentiation and migration and 3) target tissue destruction 
(Figure 1). T reg, which are implicated in immune tolerance, may mitigate 
GVHD54. This observation led to newer approaches for the treatment of 
GVHD. 
 
 
      
    
                    Figure 1: pathophysiology of acute GVHD (from Ferrara LM, Lancet, 2009)55. 
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- Chronic GVHD (cGHVD) appears usually after 100 days post-transplantation 
in around 50 % of transplanted patients. It remains a major cause of transplant 
morbidity and mortality, which is attributable to immunodeficiency, infectious 
complications and organ failure. The histological picture is characterized by 
fibrosis that can lead to the organ failure. The most frequently injured organs 
include the skin, mucous membrane, eye, liver, lung and muscles that leads to 
lichenoid and sclerodermal skin changes, mucositis, keratoconjunctivitis, 
cholestatic hepatic dysfunction, bronchiolitis obliterans and myositis, 
respectively. CGHVD may occur in three different forms: as part of a 
continuous spectrum from aGVHD (=progressive), after a free interval 
(=quiescent) or without previous aGVHD (= de novo). In 1980, a staging 
system was defined and cGVHD was classified as limited or extensive56. 
Recently, the National Institutes of Health (NIH) proposed new consensus 
criteria for cGVHD diagnosis and staging (mild, moderate, and severe)57. 
Although underlying mechanisms have not been elucidated, some factors have 
been shown to increase cGHVD risk, such as: graft from PBSCs, previous 
aGVHD, advanced age, HLA disparities, use of DLI and female donor to male 
recipient.  The latter is due to minor histocompatibility complex antigens, 
which are encoded by genes on the Y chromosome49. 
Moreover, chronic GVHD can be linked to an autoimmune syndrome. Indeed, 
auto-antibodies are generated, possibly due to the alteration of thymic function 
by previous aGVHD, previous conditioning or advanced age. The autoimmune 
T lymphocytes are not eliminated and together with alloreactive T cells cause 
tissue injuries via Th2 cytokine release such as IL-4, IL-6, and IL-10. But Th1 
cytokines are also involved (IFN-gamma and TNF-alpha). They also promote 
B-cell activation leading to the production of auto-antibodies.  
Current studies continue to analyze the involvement of donor/recipient 
genotype in transplantation outcome including in term of GVHD. For example, 
polymorphism of some single nucleotide (SNPs) or microsatellites of cytokine 
genes58-61, or other genes62, was shown to have an impact on the 
pathophysiology of GVHD. 
 
The primary treatment for GVHD consists of ciclosporine A (or tacrolimus) 
and steroids (local therapy if GVHD is classified as mild, systemic therapy if 
classified as moderate or severe); however, these immunosuppressive 
treatments are responsible for a high infection level in patients with GVHD. 
Others strategies include extra-corporeal photopheresis or the use of antibodies 
directed against TNF-alpha and IL-2. Others are currently under investigation, 
such as use of mesenchymal stem cells and B-cell suppressive agents agents 
such as rituximab. 
GVHD prevention based on T-cell depletion is to avoid because it induces an 
increased risk of graft rejection, infection and disease relapse41,63,64. Common 
immunosuppressive drugs used to prevent GVHD are methotrexate (MTX) 
combined with cyclosporine A or Tacrolimus65-68, or a combination of a purine 
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synthesis inhibitor (mycophenolate mofetill, MMF), with cyclosporine A69 or 
Tacrolimus. Anti-thymocyte globulin (ATG) infusion producing T cell 
depletion is used in the context of mismatched transplant, reduced-intensity 
conditioning or when PBSC are used.  
The important observation that patients who are suffering from GVHD have 
lower relapse rates indicates that these processes are closely linked37,38. 
Thereby, the best survival is observed for an adjusted balance between GHVD 
and GVT reaction. 
 
 
1.8. Mesenchymal stem cells 
 
Mesenchymal stem cells (MSC) are multipotent non-hematopoietic stem cells 
derived from the bone marrow and several other tissues. In vitro, they have the 
ability to differentiate into mesenchymal lineage including osteoblasts, 
adipocytes and chondrocytes70. They express surface markers such as CD73, 
CD90 and CD105 but not hematopoietic markers as CD14, CD34 and CD4571. 
In vitro, they show immunosuppresive properties; they are able to inhibit T- 
and B-cell proliferation and dendritic cell maturation and could promote 
regulatory T cells. They possess anti-inflammatory properties and release anti-
inflammatory mediators such as IL-10. Indeed, they have the ability to secrete 
paracrine growth factors and cytokines able to down-regulate inflammation. 
Moreover, the ability of MSC to differentiate into functional cells and produce 
epithelial growth factors may be a key in promoting adequate organ repair72. 
Thus, the beneficial effects of MSCs may result from the secretion of soluble 
factors rather than long-term engraftment inside the damaged tissues. Indeed, 
MSCs become rapidly undetectable after systemic administration. However, 
MSC may also act as antigen presenting cells (APCs) and pro-inflammatory 
cells. The functional polarization of MSCs seems to be dependent of the 
administration timing, the priming origin and the concentration and duration of 
the stimulus73.  
 
In the context of HSCT, MSC have stimulated a high level of enthusiasm for 
their potential therapeutic use due to their immunosuppressive activity. 
Moreover, due to their lack of major histocompatibility complex (MHC) 
molecule expression, MSC are weakly immunogenic in humans, allowing 
administration to patients without HLA matching74. Some studies have 
demonstrated that MSC infusion was safe in human75,76 and that MSCs could 
have a role in engraftment promotion and graft-versus-host disease (GVHD) 
prevention76-78.  
In recent years, there have been small studies investigating the effect of MSC 
treatment for aGHVD and cGHVD. However, Phase II and III studies 
evaluating the use of a commercial MSC product termed Prochymal® 
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(produced by Osiris Therapeutics®, Inc., Columbia, MD) in combination with 
corticosteroids to treat aGVHD gave conflicting results79,80. 
Other authors have recently shown that MSC could be successfully used for the 
treatment of severe steroid-resistant aGVHD81-83. In addition, some studies 
analyzed the usefulness of MSC as treatment for cGVHD and found that MSC 
could be an effective salvage therapy for some patients with severe 
cGHVD84,85. The real advantage of MSCs therapy to prevent or to treat GVHD 
remains, however, to be confirmed in randomized clinical studies. Moreover, 
further studies evaluating the most efficient culture condition, dose and 
schedule of administration are needed. 
 
 
 
 
 
 
 
                       
 
 
                   Rankin S., Thorax 2012 
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2. Pulmonary complications after HSCT 
 
Pulmonary complications, that are potentially lethal, occur in 40%-60% of 
patients who receive an allogeneic HSCT and account for 50% of transplant-
related deaths. Reports on intensive care outcome showed a strong association 
between mechanical ventilation and mortality after HSCT86. Complications can 
be divided into infectious and non-infectious and are classified as early or late 
depending on whether they occur before or after 100 days post- 
transplantation87. They arise as a consequence of the immunosuppressed status 
of the recipient, of the chemotherapy and radiotherapy conditioning regimens 
that precede HSCT, and of allo-immune reactions as host-versus-graft and 
graft-versus-host responses88. 
With the development of potent antibiotics and antifungal agents as effective 
prophylaxis in recent years, the spectrum of pulmonary complications has 
shifted from infectious to non-infectious etiologies. 
 
Pulmonary complications after HSCT are known to follow a predictable time 
pattern, which facilitate the diagnosis (Figure 2). 
 
 
2.1.Early complications 
 
In the immediate phase after HSCT, there is a period of profound neutropenia 
for 2-3 weeks causing mainly fungal and bacterial infections, but non-infectious 
complications are also common. 
 
 
Non infectious 
 
Pulmonary edema occurs typically in the second or third week after HSCT. 
Patients present weight gain, dyspnea and hypoxemia and the diagnosis is based 
on chest radiographic pictures. It may be due to increased pulmonary capillary 
permeability or increased pressure in these capillaries linked to the conditioning 
regimen.  
 
Engraftment syndrome develops within few days of recovery from neutropenia 
and is reported mainly after autologous transplantation. It is characterized by a 
“cytokine storm “ and clinically by fever, skin rash, diarrhea, renal impairment 
and diffuse pulmonary infiltrates. The treatment is supportive and death occurs 
in around 25% of patients. 
 
Diffuse alveolar hemorrhage (DAH) occurs around day 12 with a frequency 
average of 5% after HSCT89. It represents a common cause of acute respiratory 
failure after HSCT and often leads to hospitalization and mechanical 
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ventilation. The risk factors include intensive chemotherapy or irradiation 
before transplantation as well as older age and renal insufficiency. The 
pathogenesis involves injuries to endothelial cells of small blood vessels and 
thrombotic microangiopathy. Clinical signs include dyspnea, cough, fever and 
hypoxemia. The best tool for diagnosis is the bronchoalveolar lavage (BAL) 
fluid, which shows a progressively bloodier return, but infection must be 
excluded90. The treatment is based on empiric high doses of steroids and the 
prognosis is poor. 
 
Idiopathic pneumonia syndrome (IPS) is a diffuse lung injury with no etiology 
identified. The frequency may be up to 10% of patients91. It appears in the first 
two months following HSCT. The risk factors include older age, intensive 
conditioning regimen, high-grade aGVHD and positive donor status for 
CMV92. Clinical manifestations include fever, dyspnea, bilateral pulmonary 
infiltrates and hypoxemia. The diagnosis is based on chest imaging and BAL 
with infection exclusion. High doses of corticosteroids are used as supportive 
treatment but the mortality rate is high (70-90%)93. 
 
Bronchiolitis obliterans organizing pneumonia or BOOP (also called 
cryptogeneic organizing pneumonia or COP) is a restrictive lung disease seen 
in 1.4% of patients. It may be related to GVHD and the pathological features 
observed are the presence of intraluminal granulation in the small airways, 
alveolar ducts and alveoli94. It usually develops within 1-3 months after HSCT 
and patients present dyspnea, cough and fever. The diagnosis is based on chest 
imaging and lung biopsy. Patients with BOOP have a good response to 
corticosteroid therapy. 
 
Drug toxicity 
This is associated with some chemotherapeutic agents such as bleomycin, 
methotrexate and busulfan, and is increased when chemotherapy is associated 
with radiotherapy. It can induce acute pneumonitis and pulmonary fibrosis at a 
later stage. 
 
Infectious 
 
Due to the impaired immunity resulting from conditioning or corticosteroid 
therapy for GVHD, patients following HSCT are susceptible to develop severe 
pulmonary complications from bacterial, viral or fungal origin. 
 
Bacterial infections remain the main cause of complications after HSCT and 
are correlated with the period of granulocytopenia before engraftment. The 
main risk factors are the neutropenia, mucositis, skin damage, gastrointestinal 
failure associated with GVHD and intravenous catheters. Gram-negative 
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bacteria as Pseudomonas or Klebsiella are common in the neutropenia phase. 
Gram-positive pathogens include Staphylococcus and Streptococcus.  
Pneumocystis carinii pneumonia (PCP) can occur from the first month but its 
frequency diminishes due to better prophylaxis based on 
trimethoprim/sulfamethoxazole. 
 
 
Viral infections  
 
Cytomegalovirus (CMV) infection occurs in 70% of patients and CMV 
pneumonitis usually occurs in 10 to 40% of patients 6 to 12 weeks after HSCT. 
This period corresponds to the gradual recovery of neutrophils. The diagnosis is 
based on antigen detection by polymerase chain reaction (PCR), performed 
weekly in routine, and allows diagnosing CMV viremia before disease 
develops. The most frequent causes of infection are the reactivation of latent 
virus in a CMV seropositive patient or the transmission from a CMV 
seropositive donor to seronegative recipient. Other risk factors implicate older 
age, irradiation, ATG use, neutropenia and aGVHD. Pneumonia is the most 
severe manifestation of this infection. The associated symptoms are cough, 
fever, dyspnea and hypoxemia. Routine prophylaxis using ganciclovir in 
reactivated patients is started within the first 100 days after HSCT. Treatment 
involves ganciclovir as well, and leads to CMV control in most cases. 
 
Other respiratory viruses include respiratory syncytial virus pneumonia, which 
has a high mortality rate once pneumonia develops. Among Herpes virus, 
Herpes zoster virus (HZV) and Herpes simplex virus (HSV) may lead to severe 
infections. 
 
Fungal infections  
 
Candida species represent a commonly isolated fungal agent after HSCT. 
Routine prophylaxis uses fluconazole during the neutrophilic phase. Treatment 
uses fluconazole or amphotericin B. 
Aspergillus infection is the most common fungus leading to severe pneumonia. 
The onset of aspergillus infection is observed to occur according to a bimodal 
distribution. The first peak is at a median of 16 days and the second peak at a 
median of 96 days after HSCT. Risk factors include older age, male sex, 
transplantation outside of laminar flow room, aGVHD and corticosteroid 
therapy. Clinical features include fever, dyspnea, dry cough, wheezing, chest 
pain and sometimes hemoptysis. 
Diagnosis is suspected by chest imaging showing nodular or cavitary infiltrates 
and is confirmed by BAL or lung biopsy. The treatment of choice is 
amphotericin B or voriconazole but the mortality rate is high. 
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2.2.Late complications 
 
The immune system of the patient usually recovers to normal by 1 year leading 
to predominantly non-infectious complications thereafter. The exception is in 
case of GVHD because of then delayed immune system recovery and the 
immuno-suppressive therapy predisposing patients to infections (mainly CMV, 
encapsulated bacteria and P. carinii). 
The most dangerous late-onset non-infectious pulmonary complication is 
bronchiolitis obliterans, detailed in the next paragraph. 
 
Figure 2: Pulmonary complications according to time course after HSCT. (Adapted from Soubani 
AO, Crit Care Med 2006)95 DAH: Diffuse alveolar hemorrhage; IPS: Idiopathic pneumonia syndrome; 
BOOP: Bronchiolitis obliterans organizing pneumonia; PCP: Pneumocystis carinii pneumonia; BO: 
bronchiolitis Obliterans; CMV: cytomegalovirus; HZV: Herpes zoster virus; HSV: Herpes simplex virus. 
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2.3. Bronchiolitis Obliterans  
 
First described in 197896, bronchiolitis obliterans (BO), also known as 
constrictive bronchiolitis, occurs between 6 months and 1 year in less than 10% 
of patients after allogeneic HSCT97-101 and was proven to be associated with 
chronic GVHD102,103. However, an incidence range of 2 to 26% has been 
reported and is explained by varying diagnostic criteria and BO definition. BO 
represents a non-specific inflammatory injury affecting primarily the small 
airways but its pathogenesis remains unclear. The strong association with 
cGVHD suggests that the host bronchiolar epithelial cells serve as targets for 
donor cytotoxic T cells. Risk factors that have been associated with BO 
development include busulfan-based conditioning regimens, intensity of the 
conditioning, use of methotrexate, older age, aGVHD, long duration from 
leukemia diagnosis to HSCT, respiratory infection during the first 100 days 
(especially viral and mycoplasma infections), aspiration of oral material, HLA 
mismatch, female donor to male recipient sex match, cigarette smoking, PBSCs 
rather than bone marrow transplantation, airflow limitation prior to 
transplantation and hypogammaglobulinaemia101,102,104,105. The observation of 
heterogeneous histological findings and clinical courses implies that the most 
likely explanation is that BO has a multifactorial origin, based on allo-immune 
and non allo-immune mechanisms; it may result from events linked to 
infection, injuries (related to drugs, irradiation and ischemia) and an 
inappropriate immunological response (GHVD). 
The molecular underlying mechanism involve injury to airway epithelial cells 
(due to the conditioning, allo-reaction by donor T cells and respiratory 
infections) leading to the release of pro-inflammatory cytokines, chemokines 
and growth factors implicated in inflammatory events and chronic 
fibroproliferation. The local recruitment of inflammatory cells such as 
lymphocytes, neutrophils, and macrophages leads in turn to inflammatory and 
fibrotic process amplification. This inflammatory reaction is characterized by 
an increase in cytokines such as IL-1, IL-6, IL-8, IFN-gamma and TNF-
alpha106. 
BO is clinically recognized by the occurrence of a non-reversible airflow 
limitation within a few months that is linked to fibrosis affecting the small 
airway wall and thereby reducing airway lumen. Pulmonary function tests show 
an obstructive pattern defined by a fall of forced expiratory volume in 1 s 
(FEV1) > 20% from the pretranplantation value and a FEV1/forced vital 
capacity (FVC) ratio <0.7. Chien et al have introduced new spirometric criteria 
for BO diagnostic and suggested that annualized rate of predicted FEV1 decline 
> 5% per year and a lowest FEV1/FVC ratio < 0.8 was a better definition of 
airflow obstruction104. Diffusing capacity (DLCO) is usually reduced and the 
residual volume often increased (> 120 % of predicted value). Due to the lack 
of standardized criteria for its diagnosis, the NIH consensus included criteria 
for the BO diagnostic57 (see table 2).  
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The classic respiratory symptoms include dry cough, absence of fever, 
dyspnoea and wheezing but BO may also develop as an asymptomatic 
deterioration in pulmonary function tests in 20% of cases107. The diagnosis is 
based on the exclusion of all the causes leading to an obstructive pulmonary 
syndrome. It requires negative microbiological tests from BAL, showing 
neutrophilic or lymphocytic inflammation in case of BO, but this finding is 
non-specific108. Chest radiography is usually normal. Other chest high-
resolution computer tomography (CT) findings include signs of hyperinflation 
with decreased lung attenuation, segmental bronchial dilatation and proximal 
bronchiectasis. The hallmark is an evidence of air trapping during expiration on 
the chest scan109 responsible for a mosaic picture (Figure 3). The confirmation 
by surgical lung biopsy is rarely indicated. Histologically, the principal findings 
are granulation tissue and scarring obliterating the small airways (Figure 3). 
The inflammatory infiltrates are peribronchiolar and consist of neutrophils and 
lymphocytes. 
 
             
                         
 
Figure 3: left side: A computed tomography of the chest of a patient with 
Bronchiolitis obliterans showing air trapping. Right side: Lung pathology in 
Bronchiolitis obliterans showing bronchiolar inflammation and luminal 
obliteration associated with excess fibrous connective tissue. (From Afessa B., 
Bone Marrow transplantation 2001)107 
 
BO has a very poor prognosis with an overall survival rate of 13% at 5 years99.  
Chien et al noted that the rate of airflow decline between day 100 and 1 year 
was an indicator of mortality risk110.  
 
Due to poor understanding of its pathogenesis, the treatment is empiric and 
based on high-dose systemic corticosteroids (1 mg/kg/d) and augmentation of 
immunosuppressive therapy (cyclosporine A, mycophenolate mofetil or 
tacrolimus), but only a minority of patients shows clinical improvement.  Other 
treatment options include inhaled corticosteroids (as fluticasone), 
bronchodilators, anti-CD20 monoclonal antibodies that targets B cells 
(Rituximab), Thalidomide, ATG, anti-TNF alpha (infliximab, etanercept), 
macrolides (azithromycin), antifibrotic agent such as imatinib, leukotriene 
receptor antagonist (montelukast), total lymphoid irradiation (TLI) and 
extracorporeal photodynamic, but their potential benefits are still under 
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consideration and need reliable results111-114. Finally, lung transplantation may 
represent an option for some patients.  
Supportive treatment is essential in the management of patients with BO. 
Patients should be maintained on prophylactic measures against bacterial, 
fungal and viral infections. Moreover, appropriate vaccinations (mainly against 
influenza, pneumococcus) are recommended. Patients with advanced disease 
may require oxygen therapy and may benefit from pulmonary rehabilitation. 
 
In conclusion, further trials evaluating the efficacy and safety of these 
treatments are urgently needed to prevent the high morbidity and mortality 
associated with BO. 
Moreover, the onset of BO is insidious and the treatment appears ineffective 
once the fibro proliferative tissue process is initiated. By spirometry, the 
diagnosis of expiratory airflow obstruction indicating BO is possible only when 
the disease is widespread and advanced. Therefore there is a crucial need for 
early diagnostic biomarkers of BO, which could identify the early signs of the 
disease at a time when the patients are still clinically asymptomatic and could 
alter the course of this fatal disease. 
 
 
 
 
Table 2: diagnostic criteria proposed by NIH consensus in 2005 for BOS 
after HSCT 
 
Absence of infection 
Another cGVHD manifestation in another organ 
FEV1 < 75% predicted or > 10% decline from baseline 
Signs of obstruction:  
FEV1/FVC ratio < 0.7 or 
RV > 120% predicted or 
RV/TLC > 120%  
CT or lung biopsy with evidence of air trapping 
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Bronchiolitis obliterans occurs also and is more common after lung 
transplantation (LT).  This procedure is a well-established treatment for patients 
with end-stage pulmonary diseases and around 50-60 % of patients who survive 
over 5 years after LT develop BO115 which is responsible for the majority of 
deaths. The diagnosis is made latter in case of LT compared to HSCT (16-20 
months post-transplant). The International Society of Heart and Lung 
Transplantation proposed a clinical description of BO termed BO syndrome 
(BOS) and defined it by pulmonary function changes (fall of FEV1) rather than 
histology116. This classification was revised later due to the inclusion of a 
decrease of FEF25-75 suggested to be a more sensitive early marker of 
obstruction117. The term BOS is also in use in the context of HSCT. 
After LT, BO is regarded as the manifestation of chronic allograft rejection. 
Many risk factors are incriminated in the context of BO after LT as the number 
and severity of acute rejection episodes, respiratory infection (maily CMV 
pneumonitis), HLA disparities, lymphocytic bronchitis/bronchiolitis, 
gastroesophageal reflux and airway ischemia during the LT procedure115. 
Furthermore, genetic polymorphism may increase susceptibility to BO 
development.  
At molecular level, BO is a sequel of the host T cells (CD4 and CD8), which 
trigger adaptive immune responses against allogeneic donor lung epitopes 
(MHC class I and II). Thus, the immunopathogenesis of BO after LT is a 
“mirror” picture of the abnormalities among HSCT patients118. The allo-
immune dependent and independent mechanisms lead to a similar histological 
and clinical outcome. Damage to the airway epithelium plays a key role in the 
pathogenesis and epithelial cells are responsible for the release of IL-8, which 
is a chemoattractant for neutrophils. These neutrophils produce reactive oxygen 
species (ROS) and proteases (elastase and matrix metalloproteinases) leading to 
excessive oxidative stress and damage to lung tissue. Alveolar macrophages 
produce profibrotic cytokines that induce fibroblast proliferation and 
extracellular matrix deposition leading to obliteration of the small airways. 
The clinical and radiological findings are similar after HSCT or LT119. 
However, the transbronchial biopsy is useful and allows detecting acute 
rejection. The management is also similar as well as the high mortality rate. 
Nevertheless, in this setting, compared to BOS after HSCT, azithromycin has 
been reported to stop the progression of BOS and even improve lung 
function120, at least in patients with neutrophilic reversible allograft 
dysfunction121. 
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3. Non-invasive airway monitoring methods 
 
A close pulmonary monitoring of patients who underwent HSCT is crucial to 
diagnose complications, prevent progression of abnormalities and may guide 
therapy. 
Clinically, patients can be followed using physiological parameters assessed by 
pulmonary function tests. From biological point of view, bronchial biopsy and 
BAL are the reference methodologies to assess airway inflammation. 
Nevertheless, less invasive methods have been introduced along the years in 
order to assess biomarkers in induced sputum or exhaled air. 
 
3.1.Pulmonary function tests (PFT) 
 
In order to early detect pulmonary functions alterations, it is recommended to 
monitor the lung function tests before HSCT and at regular interval in the 
months and year following the transplantation. Patients showing abnormalities 
must be investigated for possible pulmonary infection, GVHD or BO. 
The lung function assessment prior to transplantation usually serves as baseline 
reference to evaluate the changes in pulmonary function after HSCT122.  Lung 
function can be assessed using a body box plethysmography allowing to 
measure flow rates, lung volumes and diffusion capacity according to 
ATS/ERS standard criteria123-126.  
Spirometry measures the rate of exhaled or inhaled air volume as a function of 
time.  Thereby, the measurements include the forced expiratory volume in 1 
second (FEV1) and the maximum volume of expired air after a maximum 
inhalation (forced vital capacity: FVC). The spirometry tests are performed 
before and after 400 µg inhaled salbutamol MDI administered through a 
Volumatic.  
The total lung capacity (TLC) is defined as the volume of air in the lungs after a 
maximal inspiration and the residual volume (RV) as the volume of air 
remaining in the lungs after a maximal exhalation.  
Diffusion for carbon monoxide (DLCO) is a measure of the ability to absorb 
alveolar gases into the capillary blood flow. It is depending on the alveolar 
membrane thickness, the hematocrite level, the cardiac output and the disparity 
between the ventilation and perfusion. DLCO is measured by the single breath 
wash-out technique and is corrected for the hemoglobin content. The correction 
for hemoglobin content is particularly important in HSCT patients as their 
hemoglobin levels may vary significantly over time. The lung function 
parameters can be expressed as absolute value or percentage of predicted value, 
which is calculated according to age, size, weight and gender. 
These tests allow defining three main categories of lung function abnormalities. 
Obstructive lung disease occurs when there is airway narrowing leading to 
diminished FEV1 with a preserved FVC value resulting in a decreased 
FEV1/FVC ratio (commonly < 70%). Restriction is defined by a reduction in 
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TLC (commonly < 80% predicted) with a preserved FEV1/FVC ratio. The final 
defect concerns the DLCO, which decreases in case of thickening of the 
alveolo-capillary membrane as it occurs in several restrictive pulmonary 
diseases. It may also be altered in case of peripheral ventilation/perfusion 
mismatch or neuromuscular  weakness impeding the gas to travel through the 
conducting airways. Therefore altered diffusing capacity may be observed in 
both obstructive and restrictive disorders. 
 
The lung function results before the transplantation commonly showed 
decreased DLCO values to 70-80% predicted127,128. This is possibly due to 
interstitial infiltration by the underlying malignancy, vascular changes 
secondary to the chemotherapy, irradiation129,130 or infections. 
Some studies have assessed pre-transplantation pulmonary function parameters 
as predictive factor of the outcome following HSCT. A study conducted by 
Clark et al showed a correlation between the pretransplant and 1 year 
FEV1/FVC ratio131. Others found a doubled risk of post-transplant airflow 
decline in case of either pretransplant FEV1/FVC ratio < 0.8 or the same ratio < 
0.8 at 3 months following HSCT104,110. In a large study including 1,297 
patients, an association was observed between abnormal DLCO and alveolar-
arterial oxygen gradient before HSCT and the use of mechanical ventilation and 
death after HSCT128. FEV1 < 80% of predicted value was associated with the 
occurrence of acute severe pulmonary complications following HSCT132. Low 
values of both FEV1 and DLCO pre-transplantation were previously identified 
to be associated with poor outcome after transplantation133. These two 
parameters were used by Parimon et al in the context of HSCT to establish a 
risk score for mortality134. However, this score was not validated in a recent 
study with patients receiving non-myeloablative conditioning. The authors 
found that lower pre-transplantation TLC showed a predictive value for the 
occurrence of pulmonary complications, nonrelapse mortality (NRM) and 
inversely related to overall survival (OS), while low FVC showed a correlation 
with pulmonary complications and lower OS127. A similar finding associating a 
pulmonary restriction prior HSCT and an increased risk for early respiratory 
failure and NRM after HSCT was reported in another study135. 
Overall, the current data are conflicting and did not show indisputable 
association between baseline pulmonary function parameters and early post-
transplantation outcomes136,137. Nevertheless, it is important to specify that 
most of these studies concern relatively small cohorts allowing insufficient 
power to detect associations. 
 
The pulmonary function parameters obtained early after the transplantation, 
were also linked to the occurrence of late and non-infectious pulmonary 
complications138. In an interesting study, restrictive defect at three months after 
the transplant was associated with a greater risk of death139. Others found a link 
between airflow decline by day 100 and an increase risk of airway obstruction 1 
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year after HSCT and an increased mortality risk associated with a fast rate of 
decline between 100 days and 1 year post-transplant110. A more recent analysis 
highlighted the fact that early decline in FEV1 and DLCO were linked to a 
higher risk of non relapse mortality at 5 years and that low FEV1 was 
associated with the occurrence of cGHVD within the first year after HSCT140.  
It is noted that the predictive value of pulmonary function parameters is 
different when assessed before or after transplantation due to the selection bias. 
Indeed, not all patients are able to tolerate the transplant and survive until the 
next PFT measure, others may have severe complications and the PFT may be 
not performed, explaining the different results observed. 
 
Pulmonary function abnormalities after HSCT were assessed in a systemic 
review of 20 studies published between 1983 and 1999. What came out from 
this analysis is a diminished DLCO in 83%, a restriction in 35% and an 
obstruction in 23% of patients141. Many factors could contribute to the fall in 
DLCO and to the restriction in this population: thoracic irradiation, cytotoxic 
chemotherapy, pulmonary edema, muscle weakness, GVHD, infectious or 
idiopathic interstitial pneumonia and BOOP. Obstruction was linked to several 
factors as GVHD, TBI, infection, HLA mismatch, leukemia, busulfan 
conditioning and methotrexate use. However, in a more recent cohort, the same 
research team found a lower obstruction rate reaching only 5%, possibly due to 
the introduction of cyclosporine142. 
Few studies have analyzed long term lung function variation following HSCT. 
One study described the outcome of children with leukemia or lymphoma who 
underwent transplantation conditioned with cyclophosphamide associated with 
TBI. The authors found an immediate decrease in DLCO and lung volumes, 
which recovered in the following years. Nevertheless the patients still exhibited 
subclinical pulmonary restrictive pattern at a median of 8 years after the 
graft143. In adult patients, a 5-year monitoring was performed in two studies and 
showed a reduction in lung volumes and DLCO with subsequent recovery over 
time142,144. Likewise, another study in 111 patients followed over 2 years 
showed an initial decline in lung volumes and DLCO post-transplant. Factors 
associated with a delayed lung function recovery were GHVD, pulmonary 
infections and high irradiation145.  
Discrepancies in lung function evolution after HSCT in the studies published so 
far may be related to different conditioning, different immunosuppressive 
treatments, allogeneic vs autologous transplantation and different underlying 
diseases. 
 
 
3.2.Exhaled nitric oxide 
 
Nitric oxide (NO) is a small molecule synthesized within many cells in the 
respiratory tract by NO synthases from L-arguinine. Increased NO production 
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may play antiviral/antibacterial role. The regulation of its production has been 
implicated in the pathophysiology of airway diseases. Fraction of exhaled nitric 
oxide (FeNO) is a non-invasive marker of airway eosinophilic inflammation146, 
and is correlated to the level of NO formed in airway epithelium147.  
The procedure to measure FeNO was shown to be simple and reproducible, 
allowing measurement in children and patients with severe disease. FeNO is 
measured using a chemoluminescence analyser at a constant flow rate of 50 
ml/sec (as FeNO is highly flow-dependent), in accordance with the 
recommendation of the ATS/ERS task force148. Following a full inspiration, 
seated patients (wearing a nose clip) are asked to exhale slowly from total lung 
capacity. Patients maintain a mouth pressure of 5-20 cm H2O by using a 
feedback visual display; this pressure allows closing the nasal route and avoids 
the contamination by nasal NO.  Because of the influence of spirometric 
manoeuvre on FeNO values, this measurement is performed before starting the 
lung function tests. The result is expressed in parts per billion (ppb) and is the 
average value of at least two measurements with less than 10% of variability. 
Travers et al proposed reference ranges of normal values149. However, 
concerning FeNO measurement, special caution must be paid to demographic 
and environmental cofounding factors that are known to modify the value like 
gender, atopy, cigarette smoke exposure and acute viral airway infections.  
 
FeNO values are often raised in stable asthmatics. Its clinical utility was mainly 
demonstrated in asthma to make diagnosis150,151 and predict response to inhaled 
corticosteroids (ICS) treatment152. Its role as monitoring tool to adjust ICS 
treatment is more controversial153,154.   
 
FeNO was also investigated in chronic obstructive pulmonary disease (COPD), 
a chronic inflammatory disease linked mainly to cigarette smoke. Some authors 
reported an increased FeNO level in COPD patients155, and some others found a 
negative correlation between FeNO level and FEV1 in COPD patients156. An 
association was also observed between FeNO values and sputum neutrophilia 
and IL-8157. However, FeNO seems to be less useful in COPD as it is in asthma 
as the levels often lie in the normal range in stable state and only elevate in case 
of exacerbations158,159. 
 
In the setting of LT, it is likely that the nitric oxide pathway plays a role in the 
inflammatory changes leading to BO. There is an increase level of inducible 
nitric oxide synthetase (iNOS) mRNA activity in the epithelial cells in a rat 
model of BO after LT160, iNOS being correlated with FeNO level. Similarly, 
patients with BO exhibit higher FeNO value compared to stable patients or 
healthy subjects161. The measure of FeNO after LT could be also helpful to 
assess the treatment response of BOS patients. Indeed, a decrease in FeNO 
level was reported after switching the immunosuppressive agents from 
cyclosporin A to tacrolimus and was linked to the stabilization of FEV1 and a 
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reduction of airway inflammation162. Others described an increase in FeNO 
only in early stage of the disease followed by a decrease when the 
inflammatory phase is replaced by fibrosis163. Moreover, due to its good 
reproductibility and repeatability, FeNO has been used to monitor lung 
transplantation rejection164 and was able to detect BOS several months (263 ± 
169 days) before the diagnosis based on the fall of FEV1. Others found that 
elevated FeNO levels were observed in case of unstable BOS patient resulting 
in a further decline of lung function165. This result was corroborated and 
extended by Neurohr and al who reported also a higher FeNO level in case of 
unstable non-BOS patients with future deterioration. Moreover, serial 
measurements of FeNO may provide a tool for risk stratification in these 
patients due to the excellent negative predictive value to identify patients with 
stable course166. Finally, FeNO appeared to be linked with BAL neutrophilia in 
stable and in those developing BOS after LT, confirming the finding of Gabbay 
et al167,168.  
 
FeNO has been poorly assessed after HSCT in adult patients. In the context of 
HSCT, a report showed an increased FeNO value in some patients suffering 
from BOOP169 which is suggested to be linked to GVHD as GVHD was 
associated with raised serum nitrite/nitrate levels previously170,171. A recent 
paper analysed FeNO in 68 patients following HSCT and showed a slight 
increase of FeNO 3 and 6 months after HSCT, associated with risk of death172 
but this association needs to be validated in a larger cohort. Patients of a more 
recent study had values within the normal range over time after HSCT but in 
patients with BO, they specify that others factors unrelated to BO such as atopy 
or conditioning-related lung injury could affect the FeNO value and make any 
relationship hard to detect173. In contrast, new data reported by Ditschkowski et 
al showed a decrease of FeNO in BO patients compared to patients without BO 
after HSCT and healthy subjects174. In this study, a threshold level of 15 ppb 
was able to differentiate BO from non-BO patients. In children who underwent 
HSCT, FeNO showed a predictive value for early pulmonary complications175 
after transplantation.  
 
 
3.3.Induced sputum 
 
Induced sputum (IS) is recognized as a safe and non-invasive technique to 
collect cells from airways and to assess the cellular composition as well as the 
inflammatory biomarkers in airway diseases such as asthma176 and COPD177. 
Induced sputum cell count and mediator measurements have been well 
validated178,179. Additionally, IS allows to perform a large spectrum of analysis 
such as flow cytometry180, proteomics181 and genomics182,183.  
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The sputum is induced by inhalation of hypertonic (4.5%) or isotonic (0.9%) 
saline solution according to the post-bronchodilation FEV1 value, as previously 
described184. It is not clear how the inhalation of saline produces airway 
secretions. Proposed mechanisms involve an increase of the mucociliary 
clearance and/or of the airway lining fluid osmolarity, which raises the vascular 
permeability in the bronchial mucosa inducing mucus production. 
Briefly, the inhalation is performed through an ultrasonic nebuliser (output 1-
3ml/min) after a bronchodilation using 200-400 µg inhaled salbutamol to avoid 
bronchospasm. For this purpose, additional salbutamol is also added in the cup 
of the nebulizer. The duration of the inhalation is critical as it influences the 
cell and biochemical content of the sputum sample185. Therefore, the duration 
of inhalation is standardized. The patients are asked to inhale for 3-4 periods of 
5 min and then to cough and expectorate in a plastic container at each time 
interval. Patients are also asked to rinse the mouth before expectoration to 
minimise the salivary contamination. The lung function is monitored 
throughout the induction which should be stopped in case of a decrease of 
FEV1 > 20% from baseline.  
After collection, the sample is placed on ice until lab processing, usually within 
2 hours, as recommended178. There are two options to process the induced 
sputum: the whole sample can be taken up or only the viscous part (plug) can 
be selected. Both methods are validated and reproducible but may display 
different results regarding the measure of mediators178. The use of a mucolytic 
agent such as dithiothreitol (DTT) or dithioerythritol (DTE) facilities the 
homogenization of the sample (by breaking the disulphide bonds in mucus 
molecules) and thereby the reading of the cytospin186. However, it may 
interfere with biochemical analyses179. To assess the cell composition, a 
cytospin is performed from the cell content and the supernatant is collected for 
further biochemical soluble markers analyses (as mediators, 
cytokines/chemokines). The cytology results must report the total non-
squamous cell count expressed per ml or g of sputum. The cell viability is 
assessed by trypan blue exclusion and the differential leukocyte count 
performed on cytospins stained with May-Grünwald-Giemsa on 500 non-
squamous cells using haemocytometer. The differential leukocyte count 
includes the proportion of macrophages, neutrophils, eosinophils, lymphocytes 
and columnar epithelial cells. Comparing to BAL, the sputum cell count display 
a greater number of granulocytes and a lower number of macrophages and 
lymphocytes due to a more central sampling of the airways187.  
 
Normal values in healthy adults for total cell count and differential cell count 
and cut-off points were reported188. A sputum eosinophil count greater than 2-
3% is considered as abnormal. Age of the patients was proven to have an 
impact on the sputum neutrophil count and this highlight the importance of age 
matching in comparative studies189. 
  43 
Failure to get sputum cell count can be explained either by unsuccessful sputum 
induction or by poor quality sample (squamous cell fraction greater than 80%, 
cell viability < 50%). The success rate of sputum induction even in healthy 
subjects is usually ≥ 80%190,191.  
 
In asthma, sputum eosinophil count was proposed as a diagnostic marker and 
may help in deciding about treatment options because the presence of 
eosinophils (≥3%) in the airways predicts a good short-term response to inhaled 
corticosteroids. Furthermore, it is a critical tool to define asthma inflammatory 
phenotype192.  
 
In COPD, the IS is characterized by high number of neutrophils, which is 
correlated to disease severity and increase even more in case of exacerbation193. 
Mediators were also evaluated in the sputum supernatant of patients suffering 
from asthma and COPD and confirm a predominance of Th2 cytokines in 
asthma compared to Th1 profile in COPD. 
 
In the context of LT, BAL neutrophilia and IL-8 may predate the spirometric 
criteria for BOS194 (approximately 131 days before the BOS diagnosis based on 
FEV1 decrease) and increased concentrations of various cytokines in the BAL 
were demonstrated in BOS patients195,196. However, induced sputum was 
assumed to be the most relevant compartment to study the BO 
pathophysiology197. Indeed, IS was shown to be useful in the assessment of 
chronic lung rejection after lung transplantation198. In this study, stable LT 
patients displayed higher total sputum cell count and percentage of neutrophils 
compared to healthy subjects. Moreover, in patients with chronic rejection, 
there was an increase in sputum neutrophil percentage compared to stable 
patients. Another paper reported a negative correlation between the sputum 
neutrophil count and the percentage of change in FEV1 from baseline in double 
lung transplant recipients who developed BOS. The total cell count and the 
percentage of neutrophils were also correlated with the disease severity199. 
Others confirmed this result but found also a higher proportion of eosinophils 
and chemoattractant RANTES in IS compared to non-BOS patients. In contrast 
to BAL, the IL-8 level in IS was not a useful predictive marker of BOS 
development200. This highlights the fact that BAL and IS provide different and 
complementary results, each technique investigating distinct airway 
compartments.  
 
IS has never been studied to assess the airway inflammation in patients 
undergoing HSCT. In this context, previous studies used rather BAL or 
bronchial biopsy analysis to assess the airway inflammation. A previous study 
has shown that BAL neutrophil and lymphocyte counts increased during the 
first 6 months after HSCT in patients without overt pulmonary 
complications201. Another group measured cytokines in BAL of transplanted 
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patients and showed an increased in TNF-α and IL-10 expression in BAL cells 
of patients with pulmonary complications after HSCT202. A high level of TNF-
α expression was also correlated with poor post-tranplant outcome. However, 
the BAL procedure, although well tolerated in general, has to performed with 
caution in case of fragile patients with advanced disease, because it may 
precipitate an acute airflow obstruction or pneumothorax106. Moreover, trained 
personnel and emergency equipment are needed for BAL collection. Finally, it 
remains an invasive procedure that cannot be performed as often as necessary. 
IS may be performed more frequently with lower risks and costs. 
 
 
 
 
 
 
 
 
 
 
  45 
PURPOSES OF THE STUDY 
 
In the context of HSCT, few studies have analysed the usefulness of non-
invasive techniques assessing airway inflammation such as FeNO value and 
none have investigated the potential role of induced sputum in airway 
inflammation monitoring of patients who underwent this type of 
transplantation. 
The aim of this work was to characterize both the lung function status and the 
airway inflammatory profile of patients after HSCT using FeNO and induced 
sputum. In an attempt to better understand the underlying molecular 
mechanisms linked to cellular inflammation, we also measured soluble 
inflammatory mediators in the sputum supernatant from patients undergoing 
HSCT and compared them with patients suffering from COPD and healthy 
subjects.   
In order to prevent GVHD in patients undergoing HSCT, some authors 
advocate mesenchymal stem cell co-infusion. However, some data from animal 
models show deleterious lung effects after systemic administration of 
mesenchymal stem cells. Therefore, another aim of our work was to investigate 
the functionnal impact and the infection risk in patients who underwent HSCT 
with mesenchymal stem cell co-infusion. 
 
In the first part of this project, we have conducted a prospective 
observational study looking at pulmonary function indices and airway 
inflammation using sputum analysis and FeNO measurement in patients 
who underwent allogeneic HSCT.  
 
We performed pulmonary function tests, measured FeNO value, and induced 
sputum to look at airway cell composition prior to HSCT and, 3 and 6 months, 
1, 2 and 3 years after transplantation in 182 patients.  
 
In the second part of the project, we have measured cytokines in sputum 
supernatants in patients who underwent HSCT and compared the results 
with those found in COPD patients and healthy volunteers.  
 
Fourty patients undergoing HSCT were followed for one year and a set of 
cytokines reflecting Th1, Th2 and Th17 patterns were measured in sputum 
supernatant before HSCT and after 3, 6 and 12 months. These results were then 
compared with those from 40 COPD patients and 54 healthy subjects matched 
for age. 
 
In the third part, we have investigated the impact of MSC co-infusion on 
pulmonary function after HSCT. 
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In this study, we monitored the evolution of lung function indices, FeNO and 
the occurrence of pulmonary infections and CMV reactivation in patients who 
underwent allogeneic unrelated HSCT with MSC co-infusion after non-
myeloablative conditioning. These patients were compared with patients 
matched for conditioning regimen and the type of donor but who did not 
receive MSC co-infusion. 
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Abstract 
 
Background: Patients undergoing hematopoietic stem cell transplantation 
(HSCT) display an airway neutrophilic inflammation before the transplantation 
that persists over the years. In this study, we have investigated the cytokine 
profile in sputum supernatant of patients who underwent HSCT over a period of 
one year. 
 
Methods: We have measured sputum supernatant levels of TNF-α, TGF-β1, 
IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IL-17, and IFN-γ in 40 HSCT patients by 
the multiplex technology and compared the results with those found in 40 
COPD and 54 healthy subjects matched for age.  
 
Results: Compared to healthy subjects, before the transplantation, HSCT 
patients exhibited raised levels of IL-6 (p<0.01) and IL-8 (p<0.05) while the 
other cytokines were generally poorly detectable. This picture was rather 
similar to what is seen in COPD even if cytokine levels were much greater in 
the latter with IL-8 being significantly greater in COPD than in HSCT patients 
(p<0.0001). In the 12 months following the transplantation, sputum IL-6 and 
IL-8 did not differ any longer compared to healthy subjects. However TGF-β1, 
although overall poorly detectable, was more often detected one year after 
HSCT (27%) than in healthy subjects (1%) and COPD (0%). Overall in HSCT 
patients, sputum IL-8 and IL-6 correlated with sputum neutrophil counts 
(r=0.36; p<0.0001, r=0.31; p<0.01, respectively). Baseline sputum levels of IL-
6 and IL-8 were not different in those who died over the first year (5/40) 
compared to those who survived. 
 
Conclusion: IL-6 and IL-8 may play a role in neutrophilic airway inflammation 
seen in patients undergoing HSCT. 
 
Key words: HSCT- sputum-neutrophil- cytokines-IL-6-IL-8 
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Introduction 
 
Allogeneic hematopoietic stem cell transplantation (HSCT) is now widely used 
to treat a lot of hematologic malignancies. Unfortunately, pulmonary 
complications are frequent after this type of transplantation and are a major 
cause of post-transplant mortality88. 
In a previous paper, we described the lung function status and the airway 
inflammatory profile of patients after HSCT using FeNO and induced 
sputum203. The principal observation was a progressive appearance of a 
restrictive lung function defect associated with a persistent airway neutrophilic 
inflammation after HSCT.  
While high sputum neutrophil counts have been linked to an irreversible airway 
obstruction such as that in chronic obstructive pulmonary disease204 (COPD), 
no airway obstruction was seen in patients who underwent HSCT.  
In an attempt to better understand the underlying molecular mechanisms linked 
to cellular inflammation, we measured soluble inflammatory mediators in the 
sputum supernatant from patients undergoing HSCT and compared the results 
with those obtained in COPD and healthy subjects. 
Our previous study based on the sputum and blood cell culture model 
highlighted the Th1 profile in the airway and blood compartment of COPD 
patients with raised levels of IFN-γ205.  
In this study, we undertook a comprehensive sputum cytokine analysis looking 
at Th1, Th2 and Th17 cytokines in sputum supernatant. Additionnally, we also 
measured pro-inflammatory (TNF-α, IL-6) and anti-inflammatory (IL-10) 
cytokines together with TGF-β1, a recognized factor involved in airway and 
lung remodeling. 
 
 
 
Material and methods 
 
Patients 
 
Between January 2006 and October 2011, we assessed 40 patients who 
underwent HSCT for h63aematological diseases at the University Hospital 
center of Liege and who were reassessed 3, 6 and 12 months later for their PFT 
and FeNO measurement. The characteristics of these patients are presented in 
table 1. The diagnoses were: Hodgkin’s lymphoma (n=3), non-Hodgkin’s 
lymphoma (n=11), acute lymphoblastic leukaemia (n=1), chronic lymphocytic 
leukaemia (n=4), acute myeloid leukaemia (n=12), chronic myeloid leukaemia 
(n=1), myelodysplastic syndrome (n=3), multiple myeloma (n=5). The stem 
cells were obtained from a related donor in 11 patients and from an unrelated 
donor in 29. The diagnosis of acute GVHD was based on clinical findings 
according to commonly accepted diagnostic criteria206. It was confirmed by 
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biopsy and was categorized as present (grade 2-4) or absent (grade 0-1), as 
previously described24,207. Eleven patients developed grade 2-4 acute GVHD 
and were treated with methylprednisolone. CMV infection was monitored 
weekly and if CMV PCR tests became positive (n=17), patients were treated 
with ganciclovir. 
Eight patients underwent a myeloablative conditioning regimen with either 8 
Gy single dose or 12 Gy fractionated TBI and high-dose chemotherapy. GVHD 
prevention consisted in cyclosporine A or tacrolimus with (n=4) or without 
(n=4) short methotrexate (15 mg/m2 on day 1 and 10 mg/m2 on days 3, 6 and 
11. Thirty-two patients underwent nonmyeloablative conditioning consisting in 
low-dose TBI (2 Gy) with (n=26) or without (n=6) fludarabine (90 mg/m2). 
Their immunosuppressive regimen associated tacrolimus and mycophenolate 
mofetil (45 mg/kg from day 0 to day 28 in case of HLA-identical sibling donor 
or day 42 in case of alternative donor). 
Healthy controls (n=54) were recruited by local advertisement in the hospital. 
None of them exhibited respiratory symptoms and all had normal spirometric 
results (FEV1 > 80% predicted value) and none had airways 
hyperresponsiveness (provocative concentration of methacholine causing a fall 
in FEV1 of 20 % > 16 mg/ml). They were well matched with patients 
undergoing HSCT according to age, gender and tobacco habits. 
Fourty COPD patients were recruited through the outpatient clinic and 
pulmonary rehabilitation center (University Hospital Center, Sart-Tilman, 
Liege). All the COPD patients fulfilled the criteria proposed by the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD)208 : FEV1/FVC ratio 
less than 0.7 measured 20 minutes after the inhalation of 400 µg of salbutamol. 
COPD patients were in stable condition at the time of sputum collection and no 
patients were studied within 8 weeks of having an upper tract infection or any 
exacerbations requiring change in maintenance treatment or oral steroid and 
antibiotic prescription. To avoid confounding factors influencing systemic 
inflammation, patients with significant comorbidities (such as diabetes mellitus 
or cancer) were excluded. Patients were matched to age and gender with 
patients undergoing HSCT. 
This study was approved by the Ethics Committee of the Faculty of medicine at 
Liege University and all subjects gave written informed consent for 
participation. 
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Sputum induction and processing 
 
The sputum was induced on the same day after completion of lung function 
tests by inhalation of hypertonic (4.5%) or isotonic (0.9%) saline solution 
according to the post-bronchodilation FEV1 value, as previously described184. 
The whole sputum was collected in a plastic container, weighed and 
homogenized by adding three volumes of PBS, vortexed for 30 sec and 
centrifuged at 2000 rpm for 10 min at 4°C. Supernatant was separated from cell 
pellet and stored at -80°C.  The cells were resuspended in a solution containing 
5 mM dithiothreitol (DTT) without Ca++ and Mg++ and gently shaked for 20 
min at room temperature. The cell suspension was then centrifuged again at 
1600 rpm at 4°C for 10 min and the cell count was performed using a manual 
haemocytometer. Cell viability was assessed by trypan blue exclusion and the 
differential leukocyte count performed on cytospins stained with May-
Grünwald-Giemsa on 500 non-squamous cells.  
 
Cytokines 
 
The concentrations of TNF-α, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IL-17 and 
IFN-γ were assessed by ELISA multiplex using Fluorokine® Multianalyte 
Profiling (MAP) Kits (R and D systems, Minneapolis, USA) according to the 
manufacturer’s instructions. The concentration of TGF-β1 was measured 
separately by ELISA (DuoSet, R and D systems, Minneapolis, USA). Before 
assay, TGF-β1 was activated by acidification of the samples as recommended 
by the manufacturer. Detection limits were 3.0, 10.0, 4.0, 1.0, 5.0, 1.0, 2.0, 1.5, 
5.0 and 2.0 pg/ml for TNF-α, TGF-β1, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IL-
17, and IFN-γ respectively. Spiking experiments of cytokines in sputum 
supernatants showed that recovery were 123%, 126%, 100%, 119%, 81%, 
145%, 94%, 105%, 110% and 143% for TNF-α, TGF-β1, IL-4, IL-5, IL-6, IL-
8, IL-10, IL-13, IL-17, and IFN-γ respectively. 
 
Statistical analysis 
 
Results are expressed as mean ± SD or median (interquartile range) according 
to the distribution of the data. Intergroup comparisons were made using Kruskal 
Wallis test followed by Mann Withney test in case of significance. 
Comparisons between values before and after HSCT were performed using 
Wilcoxon matched-pairs signed rank test for sputum cell counts and cytokines 
levels. Correlations between variables were assessed using the Spearman rank 
test. Differences were considered statistically significant when a two-sided p-
value was < 0.05. 
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Results 
 
a) Baseline comparison between HSCT, healthy and COPD 
As expected, COPD patients were characterized by greater total sputum cell 
counts and greater proportion of neutrophils and eosinophils compared to both 
healthy subjects and transplanted patients while patients who underwent HSCT 
were intermediate between healthy subjects and COPD (Table 2). Interestingly, 
both percentage and absolute epithelial cell counts were lower in patients 
undergoing HSCT compared to healthy subjects.  
 
Results regarding cytokines are given in table 3. Baseline levels of IL-6 in the 
sputum supernatant of patients undergoing HSCT and COPD patients were 
greater compared to healthy subjects (p<0.01 and p<0.0001 respectively) 
(Figure 1). Baseline levels of IL-8 were higher in COPD compared to healthy 
subjects and HSCT patients (p<0.0001 for both) and higher in patients with 
HSCT compared to healthy subjects (p<0.05) (Figure 2). The levels of IL-4, IL-
10, IL-13, IL-17, TNF-a and IFN-γ were undetectable in the large majority of 
patients and no difference was seen between the groups. TGF-β1 was more oten 
detected in the group of HSCT at one year than in healthy subjects (p<0.01) or 
COPD (p<0.001). IL-5 was more often detectable in COPD compared to 
healthy (p<0.01)(Table 3). 
 
 
b) Longitudinal assessment of cytokines in HSCT 
Among the 40 HSCT patients recruited at baseline for cytokines measurement, 
only fifteen produced adequate sputum samples at each visit until 1 year. This 
was due to the patient’s death or unsuccessful sputum in case of insufficient 
quantity or poor quality of the sample (squamous cell fraction > 80%) or 
sputum induction failure. Moreover, sputum induction was not performed in 
case of technical staff unavailability or patient poor health status. 
There was no significant change in sputum cell counts over the 1-year follow-
up with persistence of a high sputum neutrophil count (data not shown, in 
agreement with the results our whole cohort203).  
 
With respect to cytokines, we noted a significant decrease of IL-6 levels 3 
months after HSCT compared to baseline {n=36; from 50 pg/ml (25-89) to 32 
pg/ml (10-61); p<0.01)} but no difference was noted at 6 {n=17; from 57 pg/ml 
(31-65) to 28 pg/ml (6-68); p=0.55) and 12 months {n=15; from 41 pg/ml  (13-
71) to 44 pg/ml (13-102); p=0.84} (Figure 3). There was no significant change 
in IL-8 levels over time even if there was a trend for a reduced level at 3 
months compared to baseline. 
c) Relationship between sputum cytokines and sputum cell counts and lung 
functions. 
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When pooling all time points, IL-8 was positively correlated with the sputum 
neutrophil (n=122, r=0.36, p<0.0001) (Figure 4) and eosinophil absolute 
numbers (n= 122, r=0.35, p<0.0001) and negatively with FEV1 % predicted 
(n= 122, r=-0.32, p< 0.001) and FEV1/FVC ratio (n= 122, r=-0.35, p<0.0001) 
and FeNO (n=95, r=-0.34, p<0.01). As for IL-6, the cytokine was correlated 
with absolute macrophage (n=122, r=0.29, p<0.01) and neutrophil numbers 
(n=122, r= 0.31, p<0.01) and negatively with FeNO (n= 95, r=-0.32, p< 0.01). 
 
d) Prognostic values of baseline sputum cytokines  
Five patients out of 40 died over the 1-year period.  The level of IL-6 was 57 
pg/ml (27-279) in these patients vs 50 pg/ml (21-96) in the survivors (p=0.44). 
The level of IL-8 was 7124 pg/ml (1853-14278) in those who died vs 2039 
pg/ml (942-3657) in the survivors (p=0.14). 
 
 
Discussion 
 
Our work shows, for the first time, that patients undergoing HSCT display 
raised sputum levels of IL-6 and IL-8 compared to healthy subjects matched for 
age though the levels remained lower than those found in COPD. The other 
cytokines tested including pro-inflammatory or pro-fibrotic cytokines as well as 
Th1 and Th2 remained undetectable in the majority of patients. 
 
To the best of our knowledge, cytokines have not been measured in sputum 
from patients undergoing HSCT so far.  IL-6 is a complex cytokine involved in 
many immunological pathways. It is released in acute inflammation but plays 
also a role in chronic inflammatory process209. The cytokine is mainly produced 
by mononuclear phagocytic cells and the correlation we found between sputum 
IL-6 and sputum macrophages is in keeping with this cell source being 
important in patients undergoing HSCT. The irradiation and the chemotherapy 
prior to HSCT may be involved in the release of IL-6 into the airways of 
patients as it was demonstrated in animal models210.  In our study, the increase 
in IL-6 is slightly but not significantly lower than that seen in COPD, another 
neutrophilic airway disease, which was previously found to exhibit raised 
sputum IL-6211-213. IL-6 is thought to be pivotal in inducing IL-17 mediated 
neutrophilic inflammation214. In our series IL-17 was poorly detectable in all 
our group of patients despite satisfactory recovery in spiking experiments. Of 
interest, however, is the relationship we found between sputum IL-6 and 
sputum neutrophil counts which may confirm the link between IL-6 and 
neutrophilic inflammation. Our paired analysis of samples collected over one 
year also suggest an early decrease in sputum IL-6 levels 3 months after HSCT 
though this is not confirmed at further time points. The reduction in the 
cytokine level might be linked to starting immunosuppressive treatment like 
cyclosporine and tacrolimus, which can downregulate IL-6 expression215. Why 
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this decrease is not confirmed at 6 months and 1 year is unclear but this might 
be related to a loss of statistical power as a result of a lower number samples as 
the study went by. On the other hand, the patients for whom we obtained 
samples at 3 months but not at 6 and 12 were those who showed the sharpest 
drop in IL-6 at three months (n=19, from 54 (23-117) to 24 pg/ml (10-56) 
p<0.01). 
IL-8 is a key chemoattractant for neutrophils and its sputum level was 
repeatedly shown to be increased in a series of neutrophilic airway diseases 
such as COPD, cystic fibrosis and bronchiectasis213,216,217. Our study extends 
this series by showing raised sputum IL-8 in patients undergoing HSCT 
although the levels remained significantly lower than those found in COPD. 
The role of IL-8 in recruiting sputum neutrophils in HSCT patients was further 
supported by the clear correlation found between sputum neutrophil counts and 
IL-8 levels over the 1 year period of observation. 
Bronchial epithelial cells are known to contribute to local release of IL-6 and 
IL-8 upon activation. In our series of HSCT patients, the bronchial epithelial 
cell count appeared to be lower than that seen in healthy subjects. We can 
speculate that irradiation and chemotherapy are likely to cause injury and 
structural alteration of the epithelial layer thereby promoting release of 
cytokines involved in inflammatory cell trafficking in the airways. 
Of note is the fact that, although higher before the transplantation, sputum 
levels of IL-6 and IL-8 in the the 12 months following HSCT did not strikingly 
differ from those seen in healthy subjects, an observation that might relate to 
the strong immunosuppressive treatment received by the patients.  
We were wondering whether the baseline cytokine levels could have any 
prognosis value for the survival. The death rate at one year was 12.5% (5 out 
40) and actually rather low in the series of patients studied here compared to the 
whole cohort in which mortality at one year was 29%. Consequently, it was 
unlikely to find any statistical difference in cytokine levels at baseline between 
those who died vs those who survived even if there was trend for higher IL-8 in 
those who died. 
Other cytokines tested, including IL-4, IL-5, IL-10, IL-13, TNF-a, TGF-β1 and 
IFN-γ were poorly detectable. As aforementioned for IL-17, the poor detection 
cannot be accounted for by the use of a mucolytic agent that would have 
disturbed the immunoassay as our samples were only homogenised by diluting 
them in phosphate buffered saline. Furthermore, our spiking experiments show 
adequate recovery of all cytokines. One explanation for the poor detection may 
be linked to the fact that we used whole sputum instead of the plug thereby 
diluting somewhat the mediator concentration found in the supernatant218,219. 
Although generally poorly detectable, TGF-β1 was more frequently detected at 
one year, but not at baseline, in HSCT patients (27%) compared to healthy 
(2%) and COPD (0%). This finding could be of pathophysiological interest for 
airway tissue remodelling that may appear after transplantation but should be 
confirmed in a larger population. Similarly, IL-5 was more often detectable in 
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COPD (15%) than in healthy subjects (0%), a finding in agreement with the 
observation that some COPD may display airway eosinophilia220,221. 
There are other models looking at cytokines in the airway by using sputum 
sample. We previously showed that measuring cytokine after 24h sputum cell 
culture could provide biological signals distinguishing asthmatics222 and 
COPD205 from healthy subjects. In this model, it is noteworthy that COPD were 
shown to release more IFN-γ but less IL-6 than healthy subjects. Therefore, the 
results with IL-6 in COPD are highly discrepant depending on the model 
chosen. The difference could be explained by the fact that cellular sources that 
contribute to the supernatant content are more varied than those contributing to 
supernatant from the sputum cell culture model. Supernatant content not only 
depends on the secretion from airway cells lying within the lumen but also from 
resident structural cells and in particular from the epithelial layer, which is not 
strongly represented in the sputum cell culture. This highlights the complexity 
of the system and the caution needed before drawing definitive 
pathophysiological conclusion from cytokine measurement in the airway. 
We can conclude that patients undergoing HST exhibit a neutrophilic airway 
inflammation associated with raised sputum levels of IL-6 and IL-8, a picture 
similar but developed to a lesser extent of what is seen in COPD.
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Table 1: Demographic and functional characteristics of patients and healthy 
subjects 
 
Parameters HSCT patients 
N= 40 
Healthy subjects 
N= 54 
COPD patients 
N= 40 
 
Age (years) 
 
51 ± 12 51 ± 11 60 ± 10 
 
BMI 
 
24.6 ± 3.9 25.3 ± 5.9 26.0 ± 5.2 
 
Gender (F/M) 
 
16/24 25/29 12/28 
 
Smokers/ Ex smokers/Non-
smokers  
10/15/15 9/15/30 8/32/0 
 
FEV1 pre-BD (% pred) 
 
91 ± 15 104 ± 15 46 ± 16 
 
FVC pre-BD (% pred) 
 
99 ± 15 109 ± 17 72 ± 25 
 
FEV1/FVC pre-BD (%) 
 
76 ± 8 79 ± 4 52 ± 14 
 
FeNO (ppb) 
 
16 (13-28) 18 (14-24) 24 (15-32) 
 
Corrected DLCO (% pred) 
 
74 ± 25 ND ND 
 
Corrected KCO (% pred) 
 
88 ± 36 ND ND 
 
TLC (% pred) 
 
97 ± 12 ND ND 
 
RV (% pred) 
 
104 ± 30 ND ND 
 
Results are expressed as mean±SD except for exhaled nitric oxide (FeNO) expressed as median (IQR); BMI: body mass 
index; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; DLCO: the carbon monoxide diffusing 
capacity; KCO: the carbon monoxide transfer coefficient; TLC: total lung capacity; RV: residual volume; pred: 
predicted. 
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Table 2: Sputum total and differential cell counts in patients and healthy 
subjects  
 
Cells Pre-HSCT 
N= 40 
D100 
N=39 
 
D200 
N=28 
1 YEAR 
N=18 
Healthy 
subjects 
N=54 
 
 
COPD 
patients 
N=40 
Total cells (106/g) 
 
0.82$$$ 
(0.30-1.59) 
0.78 
(0.42-2.21) 
0.70 
(0.38-1.84) 
0.91 
(0.42-2.14) 
 
0.71 
(0.39-1.51) 
 
 
 
 
 
 
2.73
*** 
(1.23-9.19) 
Cell viability (%) 
 
70 
(58-82) 
71 
(60-85) 
68 
(50-87) 
78 
(64-84) 
 
65 
(55-81) 
 
79 
(56-87) 
Macrophages (%) 
 
30$$$ 
(21-43) 
20 
(11-51) 
28 
(20-44) 
23 
(13-37) 
 
35 
(20-57) 
 
12
*** 
(5-26) 
Eosinophils (%) 
 
0.0 
(0.0-0.6) 
0.0 
(0.0-0.7) 
0.1 
(0.0-1.3) 
0.0  
(0.0-0.1) 
 
0.0 
(0.0-0.4) 
 
0.4
** 
(0.0-2.7) 
Neutrophils (%) 
 
61$ 
(37-71) 
73 
(41-84) 
63 
(46-74) 
65 
(54-78) 
 
52 
(19-68) 
 
77
*** 
(55-93) 
Lymphocytes (%) 
 
1.3 
(0.4-3.8) 
1.2 
(0.2-2.3) 
1.7 
(0.1-3.7) 
1.5 
(0.1-2.3) 
 
1.5 
(0.5-2.8) 
 
0.7 
(0.0-1.9) 
Epithelial cells (%) 
 
1.9`
* 
(0.9-5.4) 
1.5 
(0.4-4.2) 
2.2 
(1.0-6.2) 
2.0 
(0.9-4.8) 
 
5.5 
(2.7-13.5) 
 
2.4 
(0.4-8.9) 
Macrophages 103 /g 
 
178 
(78-491) 
281 
(96-547) 
221 
(111-399) 
185 
(99-459) 
 
221 
(85-472) 
252 
(102-749) 
Eosinophils 103/g 
 
0$$ 
(0-0) 
0 
(0-1) 
0 
(0-0) 
0 
(0-0) 
 
0 
(0-3) 
 
10
** 
(0-194) 
Neutrophils 103/g 
 
300$$$ 
(197-815) 
466  
(230-1393) 
484  
(156-892) 
606 
(179-1504) 
 
276 
(78-679) 
 
2346
*** 
(646-8268) 
 
Lymphocytes 103/g 
 
11 
(2-39) 
6 
(1-48) 
11 
(1-34) 
8 
(1-25) 
 
8 
(2-29) 
 
15 
(0-30) 
Epithelial cells 103/g 
 
15
*$ 
(3-43) 
18 
(4-55) 
17 
(9-50) 
16 
(8-58) 
 
29 
(14-108) 
59 
(17-180) 
 
Unpaired comparisons, results are expressed as median (IQR).  
* < 0.05;  ** < 0.01;  *** < 0.001 vs healthy subjects 
$ < 0.05; $$ < 0.01; $$$ < 0.0001 vs COPD patients 
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Table 3: Sputum cytokine concentrations in patients and healthy subjects. 
Unpaired comparisons, results are expressed as median (IQR). D: detectable 
Kruskal-Wallis test for IL-6 gave a p value of 0.0001 and Kruskal-Wallis test for IL-8 gave a p value < 
0.0001. Then, Mann Withney tests were performed. 
* < 0.05;  ** < 0.01;  *** < 0.001 vs healthy subjects 
$ < 0.05; $$ < 0.01; $$$ < 0.0001 vs COPD patients 
 
Cytokine 
 
Pre- HSCT 
N=40 
D100 
N=39 
D200 
N=28 
1 YEAR 
N=15 
Healthy 
subjects 
N=54 
COPD 
patients 
N=40 
IL-4 
(pg/ml) 
0 (0-0) 
D= 0/40 
0 (0-0) 
D= 0/39 
 
0 (0-0) 
D= 1/28 
0 (0-0) 
D= 0/15 
0 (0-0) 
D=0/54 
0 (0-0) 
D= 0/40 
IL-5 
(pg/ml) 
 
0 (0-0) 
D= 2/40 
 
(0-0) 
D= 1/39 
 
0 (0-0) 
D= 2/28 
 
0 (0-0) 
D= 0/15 
0 (0-0) 
D=0/54 
0 (0-0) 
D= 6/40** 
IL-6 
(pg/ml) 
54
** 
(23-110) 
 
35 
(10-63) 
 
30 
 (11-94) 
 
39 
(17-87) 
 
 
25 
(13-40) 
 
 
90
*** 
(38-168) 
 
IL-8 
(pg/ml) 
 
 
2117
*$$$ 
(962-6360) 
 
2048 
(840-4235) 
1353 
(720-2461) 
2048 
(900-8249) 
 
1496 
(806-2150) 
 
 
10361
*** 
(3133-18629) 
 
IL-10 
(pg/ml) 
 
0 (0-0) 
D= 3/40 
0 (0-0) 
D= 2/39 
0 (0-0) 
D= 0/28 
0 (0-0) 
D= 0/15 
0 (0-0)  
D= 3/54 
3 (0-5) 
D= 7/40 
IL-13 
(pg/ml) 
0 (0-0) 
D= 0/40 
0 (0-0) 
D= 1/39 
0 (0-0) 
D= 0/28 
0 (0-0) 
D= 0/15 
0 (0-0) 
D= 0/54 
0 (0-0) 
D= 1/40 
IL-17 
(pg/ml) 
 
 
0 (0-0) 
D= 2/40 
 
0 (0-0) 
D= 0/39 
0 (0-0) 
D= 0/28 
0 (0-0) 
D= 0/15 
0 (0-0) 
D= 1/54 
0 (0-0) 
D= 1/40 
IFN-γ  
(pg/ml) 
 
 
0 (0-0) 
D= 3/40 
 
0 (0-0) 
D= 0/39 
0 (0-0) 
D= 0/28 
0 (0-0) 
D= 0/15 
0 (0-0) 
D= 0/54 
0 (0-0) 
D= 1/40 
TNF-α  
(pg/ml) 
0 (0-6) 
D= 11/40 
0 (0-0) 
D= 7/39 
 
0 (0-0) 
D= 2/28 
 
0 (0-0) 
D= 1/15 
0 (0-0) 
D= 10/54 
 
0 (0-19) 
D= 12/40 
 
TGF-β1 
(pg/ml) 
0 (0-0) 
D= 1/40 
0 (0-0) 
D= 1/39 
0 (0-0) 
D= 1/28 
0 (0-34) 
D= 4/15**$$$ 
0 (0-0) 
D= 1/54 
0 (0-0) 
D= 0/40 
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Figure 1: Sputum IL-6 concentrations comparison between HSCT, healthy and 
COPD 
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Figure 2: Sputum IL-8 concentrations comparison between HSCT, healthy and 
COPD. 
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Figure 3: Sputum IL-6 concentration evolution in tranplanted patients. 
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Figure 4: Correlation between sputum IL-8 concentration and sputum 
neutrophil counts in transplanted patients. The graph includes all sputum 
samples collected over the one-year period (n=122). 
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Figure 1:  Cumulative incidence of pulmonary infection (A, p < 0.01) and CMV 
reactivation (B, NS) in the MSC and control groups. 
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DISCUSSION 
 
It is well recognized that patients undergoing HSCT are at high risk of 
pulmonary complications over the months and year following the 
transplantation. The current work aimed to monitor the lung function and the 
airway inflammation in patients undergoing HSCT. To this end we applied the 
non-invasive technique of induced sputum to characterize the cellular and 
molecular inflammation prevailing in the airway of patients.  
 
In the first part of this project, we have described the modifications at airway 
level in a cohort of 182 patients who underwent HSCT. We assessed PFT, 
FeNO and sputum cell counts before and 3, 6, 12, 24 and 36 months after 
transplantation. Our main finding was the occurrence of a progressive 
restrictive pattern 3 years after HSCT associated with a sustained airway 
neutrophilic inflammation.  
Baseline functional status of our patients showed normal flow rates and lung 
volume but a slight impairement of difusing lung capacity even after correction 
for hb level. Over the follow-up, there was appearance of a progressive 
restrictive syndrome, which was confirmatory of large data base report141. The 
reasons for the restrictive pattern remain unclear but the change in lung 
function might be related to several factors such as GVHD, skeletal muscle 
weakness or sequel of recurrent lung injuries likely to occur in these immuno-
compromised patients. On the other hand, thoracic irradiation and cytotoxic 
chemotherapeutic agents are recognized factors contributing to lung fibrosis 
that may lead to restriction. MA conditioning was associated with greater 
functional restriction and greater impairement in total diffusing capacity 
compared to NMA. However, this does fit a pure restrictive change as residual 
volume increased in the first two years thereby maintaining a normal total lung 
capacity. Remarkably the ratio FEV1/FVC remained stable over the 3 years for 
the whole cohort and only a very limited number of patients exhibited BOS 
(3.5%). 
To the best of our knowledge, we are the first to report on sputum cell counts 
after HSCT. We observed an intense neutrophilic airway inflammation at 
baseline in these patients, which persisted in the months and years after the 
transplantation. This could indicate ongoing innate immune system activation 
as a result of recurrent airways micro-injuries due to irradiation and 
chemotherapy or bacterial colonisation in fragile patients because of their 
immune suppressive treatment. Indeed, the clear rise in neutrophils during the 
first year after MA conditioning may lend support to this hypothesis and might 
be related to the greater injury of respiratory mucosal system caused by the 
intense irradiation and chemotherapy. It also might be a sign of a repair process 
following aggressive therapy prior to the transplantation. It is noted that 
subclinical pulmonary infections cannot be definitely ruled out. However, none 
of subjects had overt pneumonia when assessed and the microbiological 
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analysis of sputum, when performed, did not bring out others germs than 
commensal germs. 
The neutrophils are thought to play a critical role in several lung diseases. They 
are able to release several proteases and ROS and could be therefore involved 
in lung injuries and remodeling seen in neutrophilic diseases as COPD, cystic 
fibrosis or bronchiolitis obliterans after lung transplantion. Whether neutrophils 
are involved in the change in lung function status in our patients is unclear but 
we did not see convincing relationship between the changes in sputum 
neutrophil count and the change in lung function parameters. Whether 
neutrophils could be considered as a therapeutic target to decrease airway 
inflammation in severe airway diseases is still debated because of the role of 
neutrophils in immune defence223. There has been, however, several recent 
attempts to combat neutrophilic inflammation in bronchiolitis obliterans by 
non-immunosuppressive drugs like cystéinyl-leukotrienes receptor antagonists 
(LTRA), phosphodiesterase inhibitors and azithromycine could be a strategy of 
choice. This strategy was shown successful to reverse neutrophilic bronchiolitis 
obliterans after lung transplantation121. 
Due to the persistent high sputum neutrophil percentage in HSCT patients 
compared to healthy subjects, great caution should be taken when interpreting 
the sputum composition from patients with lung complications. In order to 
avoid drawing wrong conclusions, these data should be compared with those 
obtained from a control group of HSCT patients without lung complications 
and not from healthy volunteers. 
In contrast, the value of FeNO remained in the normal range and did not change 
over time in our cohort of patients. This is not surprising as FeNO has rather 
been shown to reflect airway eosinophilic inflammation while inflammation in 
patients with HSCT is clearly neutrophilic. 
Another thing coming out from our study is the demonstration of the feasibility 
of repeated sputum in a fragile population. When pooling together all our 
sputum inductions attemps in HSCT patients, we obtained a success rate of 
73%, which is close to the figures reported in other diseases in which the 
technique has been validated such as asthma, COPD and even heathy subjects. 
Furthermore the procedure was well tolerated with no serious adverses effects 
noticed over almost 300 procedures of induction. Consequently induced sputum 
proved to be a valuable method to evaluate aiway inflammation after HSCT.  It 
can be used as a complementary method with clinical, imaging and functional 
parameters when bronchoscopy is contraindicated or when tissue samples are 
not available.  
Thus, induced sputum is a promising method for clinical and experimental 
applications in patients who underwent HSCT.  
 
In the second part of this project we have assessed the cytokine profile seen 
in 40 patients undergoing HSCT by measuring a range of cytokines using the 
multiplex ELISA technology.  
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Our data indicated that, compared to age matched healthy subjects IL-6 and IL-
8 were increased in sputum supernatant of patients before the HSCT and were 
associated with sputum neutrophilic inflammation. The levels of these 
cytokines remained however lower than those seen in COPD and it was 
especially the case for IL-8. IL-8 and IL-6 are key cytokines involved in 
neutrophilic inflammation either by direct chemotactic effect as for IL-8 or by 
promoting IL-17 pathway as for IL-6. The high levels of these cytokines in 
patients prior to transplantation are likely to result from an activation of innate 
immunity as a consequence of previous chemotherapy and irradiation. The cell 
source of these cytokine could be the epithelial layer activated by previous 
traitements. 
Baseline levels of IL-6 and IL-8 were not significantly different between 
survivors and non-survivors at one year although this finding has to be 
cautiously interpreted because the number of patients who died was very 
limited in this series (5/40). Indeed the levels of IL-8 tended to be higher in 
those who will die over the first year.  
When HSCT patients were followed up over one year (sputum samples 
assayed: 39 at 3 months, 28 at 6 months and 15 at one year), sputum levels of 
IL-6 and IL-8 tended to return to normal values. Interestingly, some patients 
with HSCT (27%) exhibited raised levels of TGF-β 1 one year after the 
transplantation whereas the cytokine remained undetectable in more than 95% 
of healthy subjects, COPD and HSCT patients prior to transplantation. Our 
finding needs caution in the interpretation as the number of sputum samples 
assayed at this time was rather low which decreases the stastical power and 
may cause a biais of selection.  
 
In the third part, we assessed the impact of mesenchymal cells (MSC) co-
infusion on lung function after HSCT. Indeed, conflicting results exist in the 
literature concerning MSC administration and their impact on the lungs.  
We evaluated the impact of MSC co-infusion on lung after unrelated allogeneic 
HSCT with NMA conditioning. We monitored the lung function, FeNO, 
pulmonary infection and CMV reactivation until 1 year in 30 patients who 
underwent HSCT with MSC co-infusion. They were compared with 28 patients 
who underwent the same type of transplantation but without MSC. 
We observed that MSC did not have deleterious effect on lung function 1 year 
after HSCT. However, the patients receiving MSC exhibited higher severe 
pulmonary infection incidence compared to controls. By multivariate Cox 
model analysis, we found that MSC could be linked to this increased 
occurrence of infections, particularly to fungal infection. 
In contrast, MSC did not favour CMV reactivation. However, it is noted that 
the patients who received MSC were all HLA-mismatch transplant cases, then 
their immune recovery could have been slower than in the control group, which 
could have caused increased pulmonary fungal infections. 
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Limitation of our work 
 
The limitations of these studies are plurial; they were limited by the 
heterogeneity of the patient group and underlying diseases and they were 
performed in a single institution limiting the patient number. 
The original part of our work is to investigate the airway inflammatory status of 
patients undergoing HSCT by using the technique of induced sputum. Although 
the technique is relatively non invasive, it has, however, not been simple to 
systematically obtain paired sputum samples of sufficient quality over the 
follow-up period for several reasons including death, poor health status of the 
patients and/or sometimes poor material collected. This has certainly limited 
the statistical power of our cell and biochemical analyses and the assessment of 
their predictive values. 
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PERSPECTIVES AND CONCLUSIONS 
 
Our current work has clearly shown that HSCT exhibit a neutrophilic airway 
inflammation associated with raised sputum IL-6 and IL-8 levels. Other 
cytokines are difficult to detect in sputum supernatants. Applying the model of 
sputum cell culture may provide additional information on the nature of 
inflammatory process operating in the airways. This model requires however a 
great number of cells recovered and is time consuming precluding its broad 
clinical application in the future. On the other hand, work focusing on 
transcriptomic should also allow giving more insight in the complex cytokine 
and growth factor network prevailing in HSCT patients.  
Our data do not support a key role in FeNO in following the HSCT as the 
values remain in the normal ranges and do not predict poor outcome. 
In addition to sputum and FeNO, other potential new markers have stimulated 
great interest and are under investigation in many pulmonary inflammatory 
disorders incuding exhaled gases or condensates224 and sophisticated lung 
function indices.  Among exhaled gases, exhaled carbon monoxide225, volatile 
organic compounds226, electronic nose227 and breathprint would worth being 
investigated as predictive markers of infections or poor outcome. In exhaled 
breath condensate, PH has been shown to be the most robust parameter so 
far228. Among lung function indices, the slope of the alveolar plateau for 
nitrogen or helium, multibreath nitrogen washout could spot the patients at risk 
of deleterious lung function evolution.  
All these potential biomarkers will have to be investigated and validated in the 
follow-up of HSCT patients in order to predict occurrence of severe infectious 
pulmonary complications, BO and death.  
 
 
In conclusion, airway monitoring is of vital importance after HSCT to evaluate 
the clinical course of the patients. It requires the use of multiple techniques that 
assess different aspects. Overall, in our series, the changes in lung function 
remain rather limited in the follow-up of HSCT with a small restriction 
appearing at 3 years. We reported the faisability and interest of induced sputum 
method after HSCT and highlighted the central role of neutrophils in airway 
inflammation before and after the transplantation, particularly in case of 
myeloablative conditioning. This neutrophilic inflammation appeared linked to 
IL-6 and IL-8 sputum level and remained less intense than in COPD patients. 
Although sputum was never collected during an overt phase of severe 
pulmonary infection, it is worth noting that cumulative incidence of significant 
pulmonary infection approaches 50% over the first year of follow-up. The use 
of MSC co-infusion to prevent GVHD did not interfere on lung function 1 year 
after HSCT but could promote opportunistic pulmonary infections. 
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